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Cardiovascular (CV) disease is a leading cause of morbidity amongst children after 
kidney transplant. The contribution of abdominal obesity and metabolic syndrome 
(MS) to CV risk is not well defined in this population.  A prospective controlled 
longitudinal cohort study was conducted to investigate contributions of obesity and 
MS to CV morbidity in a multiracial pediatric kidney transplant population.  Aims of 
the study were to 1) identify prevalence of CV and metabolic abnormalities 2) 
evaluate effects of obesity and MS on adverse CV outcomes, defined by left 
ventricular hypertrophy (LVH), impaired myocardial strain and increased carotid 
intima-media thickness (CIMT) and 3) identify the anthropometric measure of 




Circumference (WC), that best predicts CV risk.  Transplant recipients had standard 
echocardiographic measures of left ventricular size and function, strain by speckle 
tracking echocardiography, and CIMT measured at 1, 18, and 30 months post-
transplant.  35 pre-transplant echocardiograms were analyzed retrospectively. 
Multivariate longitudinal regression was used to determine associations of obesity 
and MS with CV outcomes. Results indicated obesity and MS are prevalent among 
pediatric kidney transplant recipients. WHr is a more sensitive indicator of obesity-
associated adverse CV outcomes compared with BMI or WC, due in part to the 
prevalence of short stature in this population.  Obesity, MS, and hypertension are 
associated with post-transplant LVH. Significant predictors of impaired longitudinal 
strain include obesity, hypertension, and a combination of MS with elevated LDL-C 
cholesterol, whereas higher estimated glomerular filtration rate confers a protective 
effect. African American pediatric kidney transplant recipients have increased CIMT, 
which is negatively impacted by MS, whereas the CIMT of non-African American 
children appears unaffected after transplant. In conclusion, obesity and MS adversely 
affect CV outcomes in pediatric kidney transplant recipients, highlighting the 
importance of efforts to maintain healthy weight, blood pressure, and lipid profile 
after transplant. Further studies are needed to investigate the etiology and 
consequences of increased CIMT in African American transplant recipients. Imaging 
techniques such as speckle tracking echocardiography and CIMT may provide a 
means of detecting subclinical myocardial dysfunction and provide opportunity for 
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Chapter 1: Introduction 
Objective and Rationale 
The objective of this prospective controlled longitudinal cohort study was to investigate the 
contribution of obesity and metabolic syndrome (MS) to cardiovascular (CV) outcomes in 
pediatric kidney transplant recipients. 
CV disease is the most common cause of death among young adults with childhood-onset kidney 
disease (1), and the second leading cause of death among pediatric kidney transplant recipients 
(2).  Kidney disease is a life-long chronic illness, and the subclinical risks to CV health begin in 
early childhood. Autopsy studies have identified fatty streaks and atherosclerotic lesions, 
attributable to obesity and metabolic syndrome risk factors, in the arteries of children and young 
adults who died of accidental causes (3, 4).  However, because the major CV events (such as 
myocardial infarction, stroke, or death) often don’t occur until young adulthood or later, it has 
historically been difficult to prospectively study risk factors for severe CV outcomes in pediatric 
kidney transplant recipients.  Therefore, evidence-based longitudinal research and clinical 
guidelines to identify the children at highest CV risk in this vulnerable population are lacking.  
The recent emergence of newer non-invasive technology, such as carotid intima media thickness 
(CIMT) and speckle tracking echocardiography with strain imaging, may provide the opportunity 
to accurately identify subclinical CV disease early in the course, allowing a window for early 
intervention.  The identification of the metabolic and CV risk factors that best predict subclinical 
damage (identified by CIMT and strain), are important for accurate CV risk stratification in this 
population, with the ultimate goal of delaying or avoiding the occurrence of major CV events, 







1) To identify the prevalence of metabolic and CV abnormalities in a multiracial pediatric 
kidney transplant population.  
2) To compare CV outcomes (left ventricular hypertrophy (LVH), longitudinal and  
circumferential strain, and CIMT) of transplant recipients to healthy controls. 
     3)  To investigate obesity, MS, and individual components of MS as determinants of CV         
outcomes in the transplant recipients. 
Secondary Aim 
 
1) To identify the anthropometric measure of obesity, BMI, Waist-to-height ratio (WHr), or 
waist circumference (WC), that best predicts adverse CV outcomes in pediatric kidney 
transplant recipients.   
Hypotheses 
Hypothesis 1:  
CV abnormalities including LVH, increased myocardial strain and increased CIMT will be 
prevalent among pediatric kidney transplant recipients.  
Hypothesis 2: 
CV outcomes of transplant recipients will be worse compared with controls. 
Hypothesis 3:  
Obesity and MS will contribute to risk of adverse CV outcomes in transplant recipients.  





WC for-age-percentiles may underestimate the prevalence of abdominal obesity in children of 
short stature. Impaired growth is common in children with chronic kidney disease.  Therefore 
WHr may be the most sensitive method to identify pediatric kidney transplant recipients at risk 











Chapter 2: Literature Review 
Metabolic Syndrome after Transplantation (MSAT) 
MS is the name coined for a constellation of risk factors that increase future risk of CV disease, 
stroke, and diabetes.  MS is traditionally defined as the presence of at least 3 of the following 
morbidities:  abdominal obesity, impaired glucose tolerance (reflecting insulin resistance), 
hypertension, hypertriglyceridemia, and low HDL-C cholesterol (5). The basic theory underlying 
MS is that while each individual component is an independent predictor of CV disease, the 
combination of multiple factors creates a synergistic CV risk profile that is greater than the sum 
of its parts. In the general population, studies have shown that childhood MS is a significant 
predictor of CV disease in adulthood (6).  The traditional paradigm of MS is altered by a myriad 
of factors associated with chronic kidney disease (CKD) and transplantation. In kidney transplant 
recipients, typical risk factors for MS, such as excess intake of processed foods and physical 
inactivity, converge with transplant medication-induced effects of dyslipidemia, glucose 
intolerance, and hypertension to create a hybridized version of MS unique to this population.  
MSAT has been associated with more rapid decline in allograft function over time (7-9) and 
increased risk of atherosclerotic events (10).  As such, the exact definition of MS has not been 
consistent across the transplant literature (see Table 1). A retrospective cohort study of pediatric 
kidney transplant recipients (n=234) reported that the rate of MS significantly increased from 
18% pre-transplant to 37% at one year post-transplant, using BMI rather than abdominal 
adiposity to define obesity (11).  A key finding of this study was that MS was significantly 
associated with presence of LVH at one year post-transplant (OR 2.6, 95% CI 1.2-5.9). Another 
study that investigated MS in 32 children after renal transplant did assess abdominal obesity, but 





were obese.  The fact that the majority of children determined to have MS in this study were lean 
suggests the involvement of individual transplant-related risk factors other than obesity at play in 
recipients (12).  Therefore, MSAT differs from the classic model of MS, and the interplay of its 
individual components in pediatric transplant recipients is unclear.   
 
Table 1: Summary of studies on metabolic syndrome in pediatric kidney transplant 
recipients 




2009 >3 criteria: 
 WC>75cm 





 TG>90th%ile or 
on statin 
 Glucose>140 
mg/dl (3h OGTT) 
25% 
(8/32) 
 Higher proportion 












2010 >3 criteria: 
 BMI>97th%ile 
 BP>95th%ile or 
on BP med 
 HDL-C<5th%ile 
or on statin 




mg/dl or on 
insulin 
18.8% at tx 
(34/181) 
 
37% at 1 year 
post-tx 
(67/181) 
 Higher odds of 
LVH (OR 2.6) 
 





et al(8).  
2010 >3 criteria: 
 BMI>97th%ile 
 BP>95th%ile or 
















 Lower eGFR in 
children at 1 year 
post-transplant 
(65) versus those 












2014 >3 criteria: 
 >120% median 
weight 
 BP>95th%ile or 
on BP med  
 HDL-C<40mg/dl  








14.2% at 5 yr 
post-tx 
(18/127) 
 Lower eGFR at 
1.5 yrs, but no 
difference  at 5+ 
years post-tx 
Abbreviations: BP: blood pressure, TG: triglycerides, OGTT: oral glucose tolerance test 
Individual Components of Metabolic Syndrome and kidney transplant recipients 
The following section will discuss the individual components of MS and how they manifest in 
pediatric kidney transplant recipients.  
Obesity 
Childhood obesity is a significant issue affecting the general pediatric population, with recent 
estimates indicating that 16.9% of US children are obese (13).  A cross-sectional analysis of 
national data representing US children ages 6-17 years old revealed that obese children are at 
higher risk for dyslipidemia, glucose intolerance, and hypertension compared with healthy-
weight children (14). It is projected that by 2025, approximately 268 million children will be 
overweight, including 91 million obese world-wide. These children are expected to have obesity-
related comorbidities, including impaired glucose tolerance, type 2 diabetes, and hypertension 
(15).  Causes of obesity include poor diet and physical inactivity, as well as genetic factors; 
genome-wide analysis studies have recently identified more than 90 susceptibility loci for BMI 
(16).   
Obesity is known to increase CV risk in both children and adults. The pathology of obesity-





factor-alpha (TNF-, from adipose tissue. The inflammatory cytokines induce a variety of  
unfavorable effects including endothelial dysfunction, glucose intolerance, vasoconstriction, and 
vascular dysfunction, all of which increase CV risk (17).   
BMI (kg/m
2
) percentile-for-age is the most common method used to diagnose overweight (85
th
-
95th percentile) and obesity (>95
th
 percentile) in children (18).  However, abdominal obesity, 
measured by WC or WHr, is more strongly associated with high metabolic and CV risk than is 
high BMI in the general pediatric population (19-21).  However, each of these anthropometric 
methods has limitations, particularly in reference to the assessment of children with CKD.  
Studies have shown that BMI does not accurately reflect body composition in children with 
CKD, due to their altered body habitus characterized by reduced lean mass and high fat mass, as 
revealed by Dual X-ray Absorptiometry (22, 23).  However, waist circumference-for-age 
percentiles are likely to underestimate abdominal obesity in children with CKD, since impaired 
growth and short stature are common. Therefore more sensitive anthropometric methods are 
needed to accurately diagnose obesity in this population. 
Obesity trends in children with CKD mirror those in the general pediatric population. In a recent 
analysis of 799 children who participated in the Chronic Kidney Disease in Children (CKiD) 
study, 15% were overweight and an additional 18% were obese (24).  In this CKiD cohort, 
median height and weight SDS were -0.55 and 0.03, respectively, and 12% had severe short 
stature (SDS <-1.88). The combination of short stature with preserved or above average weight 
compound the risk of obesity in this population (24).  
Obesity is even more common in the pediatric transplant population, and studies show that the 
prevalence of obesity doubles (from about 15-30%) during the first year after transplantation 





improved taste sensation with the resolution of uremia, liberalization of renal diet restrictions, as 
well as sedentary lifestyle and poor overall physical fitness, which are pervasive in this 
population (25).  Obesity in pediatric transplant recipients has been associated with decreased 
allograft survival and increased mortality.  Nutrition education and counseling to promote a 
heart-healthy diet and regular physical activity, with a goal of at least 60 minutes of active play 
daily, are recommended to promote maintaining healthy weight and decreasing CV risk after 
transplant (26).    
Hypertension 
Hypertension is a major cause of end organ damage and CV morbidity and mortality in the 
general pediatric population as well as in children with renal disease. A recent evaluation of 
trends in pediatric hypertension based on a large sample of NHANES data indicates that the 
prevalence is increasing and is associated with the childhood obesity epidemic across the United 
States (27). The strong link between obesity and hypertension is substantiated physiologically.  
The release of angiotensinogen by adipose tissue promotes increase in blood pressure via 
stimulation of the renin-angiotensin-aldosterone system (RAAS) and increased sodium 
reabsorption in obese individuals (28). In pediatric kidney transplant recipients, hypertension risk 
is further compounded by effects of immunosuppressive medications.  Corticosteroids are known 
to increase sodium and water reabsorption and increase in renal vascular resistance, while 
calcineurin inhibitors (CNI) induce hypertension via afferent arteriolar constriction, stimulation 
of RAAS,  and secretion of  inflammatory cytokines leading to fibrosis of the allograft over time 
(29). 
As such, the prevalence of hypertension in the pediatric kidney transplant population is strikingly 





61% had hypertension at 1, 5, and 10 years post-transplant, respectively (30).  Hypertensive 
children at 10 years post-transplant had 8.1 times higher risk of graft loss compared to 
normotensive children (30). Hypertension has been associated with increased CIMT and 
myocardial strain in otherwise healthy children (31, 32), and in pediatric kidney transplant 
recipients (33).  As hypertension is a key component of MSAT, frequent blood pressure 
monitoring and aggressive treatment of hypertension are critical to mitigating CV risk in 
pediatric transplant recipients.  
Dyslipidemia 
Dyslipidemia is a strong risk factor for CV disease, and compelling evidence from autopsy and 
cohort studies in the general population indicate that atherosclerotic lesions silently begin to 
develop during early childhood (4, 34, 35). Individuals with MS typically exhibit a highly 
atherogenic lipid profile characterized by hypertriglyceridemia and low HDL-C cholesterol, 
which frequently occur together in association with obesity and physical inactivity. Dyslipidemia 
is common in children with CKD and after kidney transplantation. In a study of 366 children 
with CKD, 32% had hypertriglyceridemia, 18.3% had low HDL-C cholesterol, and  
hypertriglyceridemia independently predicted increased CIMT, and indicator of increased risk 
for CV disease (36).  
After transplantation, the risk of dyslipidemia is compounded by the effects of commonly used 
immunosuppressive agents, including corticosteroids, CNI and mTOR inhibitors. A recent 
registry study of 386 pediatric kidney transplant recipients reported hypertriglyceridemia in 71% 
of children at 3 months post-transplant, 59% at 1 year post-transplant, and hypertriglyceridemia 
was associated with lower GFR(37).   Corticosteroids alter lipoprotein metabolism and promote 





(38).  A dose-dependent effect of CNI on increased lipid levels has also been demonstrated in 
adults, however use of tacrolimus has generally been associated with a more favorable lipid 
profile in comparison to cyclosporine (39).  In pediatric patients, the use of  immunosuppressive 
regimens containing cyclosporine,  mTOR inhibitor, and steroids was associated with at 25-fold 
increased risk of dyslipidemia compared with a regimen of tacrolimus, mycophenolate, and 
steroids (37). The overall high CV morbidity in the pediatric transplant population places them at 
high risk for early-onset CV disease, as categorized by the National Heart, Lung, and Blood 
Institute (NHLBI) expert panel, warranting close monitoring of lipid levels, lifestyle and dietary 
interventions. (40). Obese children without kidney disease are also included in the NHLBI high 
CV risk category, therefore compounding the projected CV risk among obese children with 
MSAT. The first line of management for dyslipidemia characterized by high triglycerides with 
low HDL-C should focus on weight management, including limited intake of saturated fats and 
simple sugars, and increased physical activity(26). Although there are no current 
pharmacological treatments for lowering triglycerides in children, limited data on the beneficial 
effects of omega-3 fatty acids may hold promise as a future therapy (26). In addition, adjustment 
of the immunosuppression regimen may be considered judiciously.    
Impaired Glucose Tolerance  
Impaired glucose tolerance can lead to vascular endothelial dysfunction, dyslipidemia, 
hypertension, and vascular inflammation and hence promote the development of CV disease.  In 
a study of moderately obese adults with varying degrees of insulin sensitivity, those with the 
highest insulin resistance were found to have the highest CV morbidity (41).   After 
transplantation, glucocorticoids induce peripheral insulin insensitivity while CNI cause an 





stage for impaired glucose tolerance.  In children, it has been reported that 26.2% have impaired 
glucose tolerance and 8.1% develop new onset diabetes after transplantation (NODAT) by 6 
months post-transplant (43).  NODAT is associated with abdominal obesity and MSAT, and has 
also been linked with increased risk of CV events after transplant (42, 44-46).   
The KDOQI pediatric guidelines recommend that patients should be counseled on a diet low in 
simple sugars, avoiding juices, soda, and other sweetened beverages to minimize the risks of 
excess weight gain and hyperglycemia post-transplant (26). 
Racial differences in MS and CV risks 
Individuals of African descent generally carry higher risk for MS, CV disease, and kidney 
disease than other races (13, 47-49).  The reasons for these disparities are not completely 
understood, and are likely multifactorial in nature.  Genetic factors are known to play a role, due 
to the strong association of the Apolipoprotein L1 gene (APOL1) with risk of CKD in 
individuals of African ancestry. Relationships of APOL1 renal risk variants with increased risk 
of CV disease among those of African descent are also starting to emerge (50). In the Women’s 
Health Initiative study of 749 postmenopausal A-A women, those with 2 APOL1 alleles had a 
lower GFR and higher risk for incident CVD compared to those with 0 APOL1 alleles (OR 1.98, 
p= 8.37x10
-3
)(51). New insights into the role of genetic factors and obesity are also being 
uncovered as genome wide association studies (GWAS) delve into this area.  Recently, the first 
GWAS for BMI in individuals of African descent identified a novel BMI locus known as 
“SEMA4D”, which appears to promote obesity through regulation of a transcription start site, 
and may explain some of the increased burden of obesity among this population (52).   Beyond 





groups may include environmental exposures, cultural beliefs, psychosocial factors, and access 
to healthy whole foods and health care.  
A-A adults, including young adults, have higher rates of adverse CV events and CV death 
compared with other racial groups (53, 54).  Evidence shows that A-A have higher LV mass 
compared with other racial groups (55).  Looking at subclinical markers of CV disease, studies 
have shown that CIMT is higher among healthy adults and children of African ancestry 
compared to other ethnicities (56, 57).  A recent cross-sectional study by Lefferts et al. examined 
racial differences in CIMT and aortic stiffness, measured by pulse wave velocity (PWV) in 
healthy children (58). This study reported higher PWV and CIMT in A-A children compared 
with Caucasian children after adjustment for age, sex, blood pressure, and socioeconomic status. 
The etiology of increased CIMT in this population is unknown.  It remains to be seen whether it 
may be related to environmental exposures, genetic polymorphisms, or other causes. One study 
suggests that higher CIMT among individuals of African ancestry may be related to 
physiological differences in the size of CV structures and lean body mass that vary among 
different ethnic groups (59), while another study concluded that a blunted nocturnal cortisol rise, 
caused by psychosocial stress, may account for increased risk for atherosclerosis and CIMT in 
obese A-A youth (60).    
Few studies have investigated ethnic differences in myocardial strain. The Multi-Ethnic Study of 
Atherosclerosis, a prospective, observational cohort study of 6814 healthy adults representing 
four ethnic groups (Caucasian, A-A, Hispanic and Chinese-American), investigated racial and 
ethnic differences in subclinical myocardial function using cardiac magnetic resonance imaging 
(CMR). A-A were found to have the least favorable systolic strain, even after correcting for 





tri-ethnic (A-A, Hispanic, and Caucasian) healthy population with normal EF, and similarly 
found that A-A had the greatest degree of subclinical LV systolic dysfunction detected by 
longitudinal strain (61).   
Recent evidence suggests that the relationship and degree of synergy between individual 
metabolic risk factors vary greatly among different ethnic groups(62). Little is known about race-
specific factors impacting MSAT in pediatric kidney transplant recipients.  Given the high rate of 
metabolic derangement, CV morbidity, and end stage renal disease (ESRD) among those of 
African ancestry, future studies should investigate how the effects of transplant-related factors on 
cardiometabolic risk differ amongst pediatric kidney transplant recipients of different ethnicities.  
These differences add another layer of complexity and should be further investigated in order to 
establish race-specific guidelines for defining MSAT and evaluating CV risk in a diverse 
population of pediatric transplant recipients.       
Evaluation of CV Disease  
Traditional evaluation by standard echocardiography 
The detection of overt abnormalities in standard measures of systolic LV function by 
echocardiography, such as ejection fraction (EF) or fractional shortening (FS), are rare in the 
pediatric population (25). Even among children with obesity and MS, EF is typically found to be 
normal (63).  The presence of abnormal EF or FS in a child would indicate that advanced CV 
disease is already present.  Evaluation of LV mass by traditional echocardiography is also of 
limited use in detecting CV dysfunction in children with CKD, due to its lack of accuracy in 
young children, underestimation of LVH in overweight patients, and lack of reliability in fluid 
overloaded patients.  Recent evidence is emerging to suggest that subclinical CV abnormalities 





for newer, more sensitive tools such as speckle tracking echocardiography and CIMT for early 
detection of CV dysfunction in pediatric kidney transplant recipients.  
Left Ventricular Hypertrophy (LVH) 
LVH has traditionally been considered important in the identification of CV risk.  LVH can 
develop early in the course of CKD, and often persists after kidney transplant, particularly in 
association with MSAT.  A retrospective study of 234 pediatric transplant recipients reported a 
40% prevalence of LVH and 2.6 times greater risk of LVH in recipients with MS than in those 
without MS (11). However, there is no consensus on the best way to define LVH in young 
children, due to the significant changes in the relationship of their height to body and heart size 
with rapid growth, nor in the pediatric kidney transplant population, due in part to their abnormal 
body composition and short stature (64). LV mass normalized to height
2.7
 is a commonly used 
method to evaluate LVH, as it describes the relationship between heart and body size without 
obscuring effects of obesity.  In children > 10 years of age, LVH is defined as >40g/m
2.7
 in girls 
and >45 g/m
2.7
 in boys. However, this method is not reliable in children under the age of 10 
years, and in addition may underestimate relative LVM in thin children and overestimate LVM 
in overweight children (65-67).  To address this limitation, Khoury et al. developed normal age-






 percentile for age to define 
LVH (66).  Subsequently, Foster and Khoury et al. developed new LV mass reference percentiles 
expressing LV mass relative to lean body mass, which is the strongest determinant of LV mass 
(68). Thus, while some studies have reported improvement in LVH after transplant, findings 
have been inconsistent across the pediatric literature, due in part to the limitations discussed. 
Table 2. Summary of studies on LVH by echo in pediatric kidney transplant recipients 
Author 
Year 
Design Definition of 
LVH 















%ile for age 
and gender 
54% at 14 
months post-
tx*; no change 
at 33 and 49 
mo. 
(n=47) 
SBP and BMI predicted LVH. 
LVH prevalence remained 
unchanged, but LVMI 
















LVH decreased after tx, and 
was related to baseline LVM 










Authors noted lower 
prevalence of LVH compared 
with other studies. Insufficient 








) > 2 
SD above mean 
for age 
54% pre-tx, 
23% 3 months 
post-tx,  8% yr 
2 post-tx (n=13) 




LVM and prevalence of LVH 
improved after tx, but not in 
those who remained on 
dialysis.  











%ile for age 
and gender 
18.8% at tx 







Prevalence of LVH increased 
from 18.8% to 37% in first 
year post-tx. 
Metabolic syndrome strongly 
associated with LVH. 
McLaughli
n et al.(73) 
2014 






ile for age 
and gender 
2)Children>9 yrs 
as above; for 
children<9 yrs,  
>40g/m
2.7















Prevalence of LVH improved 
after tx but individual trends 
highly variable. 
Prevalence also varied by 







 z-score > 1.645 
Improved from 
48% to 35% 
from 1 to 2 yrs 
post-transplant 
LVM improved in those on 
steroid avoidance vs steroids 












et al. (75) 
2016 









29.2% 6 months 
post-transplant 
(n=24) 
No significant change in 
















(n=25, 11 CKD 
and 14 
transplant) 
Echo overestimates LVH 
compared to CMR. 
CMR-LVM is correlated with 
future eGFR decline, echo-













No change in LVM pre vs. 
post-transplant. 
LVM of transplant patients 
greater vs. controls. 
*Transplant is abbreviated as tx 
 
Novel imaging tools for early detection of CV morbidity 
Carotid intima media thickness (CIMT)  
CIMT has emerged as a reproducible surrogate marker for early atherosclerosis (78). Non-
invasive imaging of the carotid arteries is used to demonstrate the status of the intima-media 
thickness of the vessel.  Prospective studies have demonstrated that an increase in CIMT is 
associated with an increase in the relative risk for stroke and myocardial infarction in the general 
adult population (79, 80).  Increased CIMT has been found to be associated with MS and its 
components (hyperlipidemia, hypertension, obesity, type I diabetes) in the general pediatric 
population (81). Woo et al. conducted a study investigating the effect of diet and exercise on 
noninvasive markers of atherosclerosis in otherwise healthy obese children, and found a 





that a significant change in CIMT can be detected after a 1 year period (82).  Studies of CIMT in 
pediatric kidney transplant recipients are summarized in Table 1. Two recent studies 
investigating CIMT in pediatric renal transplant recipients found that CIMT was significantly 
greater compared to healthy controls, and CIMT correlated with duration of dialysis prior to 
transplantation (83, 84). Litwin et al. reported that CIMT of children with CKD or on dialysis 
increased by 0.7 SD over a period of one year, while CIMT improved by an average of 0.6 SD 
within one year in those who received kidney transplants (85).  The CIMT of pediatric transplant 
recipients of African ancestry has not been previously reported.  Only two of the nine previous 
studies summarized below included a small number of A-A patients, the CIMT of the A-A 
recipients was combined with other races in the analysis.  
Table 2. Summary of studies on CIMT in pediatric kidney transplant recipients 










31 tx*/31 control 
(Cincinnati,OH) 






























24 tx/20 control 
(Turkey) 
0 CIMT 
















0 CIMT tx 
decreased 
over time 










31 tx/21 control 
(Sweden) 































13 tx/26 control 
(Finland) 









66 tx/66 control 
(Iran) 




























58% of tx 
None 
identified 
*Tx indicates an abbreviation for transplant recipients. 
Myocardial strain by speckle tracking echocardiography  
Assessment of myocardial strain by speckle tracking echocardiography utilizes new technology 
to analyze myocardial motion by tracking natural acoustic markers (or speckles) as they move 
during myocardial contraction (93).  Strain is emerging as an important, non-invasive tool for the 
assessment of LV systolic function.  Its key advantage is the ability to detect early signs of LV 
dysfunction that are not evident by standard echo. In addition, strain analysis is load- 
independent, making it well-suited for evaluation of myocardial function in children with kidney 
disease. Recent evidence indicates that subclinical myocardial dysfunction, detected by impaired 
myocardial strain but not by standard echocardiography, is present in otherwise healthy children 
and young adults with obesity, hypertension, and type 1 diabetes (63, 94-98).  Impaired strain 
has also been shown to be indicative of early myocardial dysfunction in septic shock in children 
(99) of prognostic value for myocardial recovery after myocardial infarction (100), and an 





was a strong independent predictor of mortality in a recent study of adult hemodialysis patients 
with preserved EF, further supporting the utility of speckle tracking echocardiography in 
identifying early subclinical CV risk (102).  Little is known about the myocardial strain of 
pediatric kidney transplant recipients. To date, three studies investigating myocardial strain in 
children with CKD have been published in the literature.  The Cardiovascular Comorbidity in 
Children with CKD (4C) study investigated myocardial strain in 272 children with CKD in 14 
European countries compared with 61 healthy controls (103).  They found that despite having a 
normal EF, the myocardial strain of children with CKD was impaired in the radial and 
circumferential directions.  In addition, LVH was more common in the children with CKD 
compared with controls (55% versus 7%, p= 0.001), and the LVH geometry was preferentially 
concentric. There were no differences noted in longitudinal strain between the CKD and control 
groups.  The authors hypothesize that the concentric LVH may have occurred as a response to 
impaired circumferential function, possibly suggestive of intrinsic structural abnormalities of the 
heart muscle in children with CKD. Another recent cross-sectional study investigated myocardial 
strain in children with ESRD (19 dialysis patients and 17 transplant patients) compared with 33 
healthy controls (104).  This study similarly found no differences in EF between patients and 
controls, but significantly increased LV wall thickness and impaired myocardial strain in the 
dialysis and transplant patients compared with controls.  The myocardial dysfunction in the 
dialysis and transplant groups was characterized by impaired longitudinal strain, while 
circumferential and radial strain did not differ from controls.  This is in contrast to the findings of 
circumferential dysfunction in the CKD population reported by the 4C study, and may reflect 
different LV mechanics during different stages along the continuum of renal disease.  Looking 





in 48 children at 3 different time points: CKD, dialysis, and 1 year post-transplant compared with 
192 healthy controls (77).  Results of this study indicated that ejection fraction of children was 
similar to controls, and remained normal throughout dialysis and transplantation.  Longitudinal 
and circumferential strain parameters were similar to controls during CKD.  Longitudinal strain 
worsened during dialysis (β=2.0, 95% CI 0.4-3.6), but the association was not significant after 
adjustment for blood pressure and CKD.  Following transplantation, longitudinal strain improved 
back to CKD levels.  
The existing data on myocardial strain is limited, but suggests that children with CKD have 
subclinical myocardial dysfunction that develops during the course of CKD, worsens during 
dialysis, and may persist after kidney transplantation. In children, the signs of myocardial 
dysfunction are typically not apparent by standard echocardiography, but subclinical 
abnormalities are detectable by speckle tracking echocardiography. The investigation of strain in 
the pediatric kidney transplant population is of particular importance, as it may provide an 
opportunity to identify those children at highest risk and provide an opportunity for early 
intervention.  The studies discussed above were limited primarily to Caucasian populations. 
Pediatric kidney transplant recipients of African ancestry are an underrepresented group that 
should be included in future studies.   
 
 





Chapter 3: Methods 
 
Study Design 
A prospective, controlled, longitudinal cohort study was conducted. An overview of the study 
design is presented in Figure 1. 
IRB Approval and Informed Consent 
The study was conducted at Children’s National, a pediatric hospital and kidney transplant 
center, located at 111 Michigan Avenue NW, Washington DC, 20010. Approval was obtained 
from the Institutional Review Board (IRB) at Children’s National and from the IRB at University 
of Maryland College Park. All investigators completed the Collaborative Institutional Training 
Initiative Social and Behavioral Research Basic course, an IRB required ethics course. Informed 
consent was obtained from all participants over the age of 18 years and parents of those 
participants under the age of 18 years.  Informed assent was obtained from all participants 
between the ages of 7 to 18 years, in accordance with the policy of Children’s National IRB. 
Participants did not receive any financial compensation for participating in this study. 
Study Participants  
Transplant Study Group  
Children who received a kidney transplant at Children’s National, age 3-20 years, were eligible 
to participate in the study, with a goal to enroll a minimum of 24 transplant patients (10 obese, 
14 lean), with an allowance for additional enrollment to account for the possibility of loss to 
follow-up due to the longitudinal nature of the study. Transplant recipients were eligible to enroll 







 Age 3-20 years  
 Kidney transplant recipient at Children’s National 
Exclusion criteria 
 Diagnosed with diabetes prior to transplant 
    Multi-organ transplant 
 Underlying heart disease (to be excluded from standard echo and strain 
analysis only) 
 Estimated Glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 
 Recurrent Focal segmental glomerular sclerosis with nephrotic range 
proteinuria post-transplant 
 
Healthy Control Group   
In addition, 24 healthy children were recruited to serve as controls. 
Inclusion criteria 
 Healthy non-obese children  
 Age 3-20 years 
 Normotensive 
Exclusion criteria 
 History of heart, kidney, or other chronic disease 
 Obesity 
 Hypertension 





Anthropometric measurement  
Weight, height, and waist circumference were measured at 1 month, 18 months, and 30 months 
post-transplant.   
Weight and Height 
Weight and height of each participant were measured by a trained pediatric nurse according to 
standard procedure in the Heart and Kidney Clinic at Children’s National at each study visit.  
Weight was measured to the nearest 0.1 kg using a digital scale (Scale-tronix, Dynamic Scales, 
Inc., Terre Haute, IN), which was routinely calibrated according to Children’s National 
standards.  Height was measured to the nearest 0.1 cm using a stadiometer with sliding 
perpendicular head piece affixed to the wall (The Standard Stadiometer, Perspective Enterprises, 
Portage, MI).  The stadiometer was routinely calibrated according to Children’s National 
standards.  
The participant was instructed to remove shoes, and touch posterior heel, buttocks, shoulder 
blades and head to the vertical board of the stadiometer. Frankfurt plane positioning of head was 
ensured.  
Waist Circumference  
Waist circumference was measured to the nearest 0.1 cm by a trained registered dietitian (Kristen 
Sgambat, MS, RD) at each study visit using a Gulick IIR fiberglass tape measure (Country 
Technology, Gays Mills, WI).  Waist circumference was measured at the upper-most lateral 
border of the right ileum, at the end of an expiration, according to the NHANES procedure 






Presence of obesity was then  assessed by three different methods: BMI, waist circumference 
(WC), and waist:height ratio (WHr).  Patients in the transplant group were stratified to the obese 
or non-obese group, based on the following criteria: 
 BMI was calculated as weight (kg) divided by height (m2) and was converted to age-and-
sex specific percentiles and z-scores based on the 2000 Centers for Disease Control 
(CDC) growth charts, with BMI>95
th
 percentile defined as obese (18).  
 WC waist circumference percentiles were determined according to CDC age-and-sex 
specific tables and obesity defined as waist circumference >95
th
 percentile (106).   
 WHr was calculated as a simple ratio of weight in cm divided by height in cm. A WHr 
cut point of >0.539 was used to classify obese, based on NHANES III data according to 
the method of Kahn et al. (19).  
C. Evaluation of metabolic and CV parameters 
Blood Pressure and Hypertension   
All transplant patients had systolic and diastolic morning blood pressure measured at 1, 18, and 
30 months post-transplant, as shown in Figure 1.  Blood pressure was measured by a trained 
pediatric nurse using an automated mobile blood pressure device with age- and-size-appropriate 
cuff (Mobile Aneroid model 767, Welch Allyn, Skaneateles Falls, NY). Seated blood pressure 
measurements were taken on the right arm, with the participant’s arm extended at heart level.  
Systolic and diastolic blood pressures were recorded to the nearest 1 mmHg. 
Prevalence of “hypertension” and “uncontrolled hypertension” were determined in the transplant 
group.  Hypertension was defined as a patient requiring anti-hypertensive medication on a 







 percentile for age, sex, and height for those 2-18 years old (107) and >130/85 mm 
Hg for those >18 years old (irrespective of taking blood pressure medication).  
Dyslipidemia   
All transplant patients had a fasting lipid panel, which included total cholesterol, direct LDL-C 
(not calculated), HDL-C, and triglycerides measured at 1, 18, and 30 months post-transplant 
(Figure 1).  Patients were instructed to fast, with nothing to eat or drink except water, for 12 
hours prior to the 9 am morning lab draw.  For this test, participants had 1 mL of blood drawn at 
Children’s National Laboratory. Blood was drawn in a red top tube and centrifuged to obtain a 
minimum of 0.5 mL plasma. The samples were analyzed using a Siemens Dimension EXL 
Chemistry Analyzer by enzymatic method. 
Prevalence of dyslipidemia was determined in the transplant group. Abnormal lipid levels were 
defined according to the following: 
HDL-C and LDL-C 
 Ages 3-19 years: HDL-C <40 mg/dL or LDL-C >130 mg/dL based on 2011 Expert Panel 
Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and 
Adolescents, or on lipid lowering therapy  (40). 
Pediatric Triglycerides 
 Ages 3-9 years: Triglycerides >100 mg/dL (40). 
 Ages 10-19 years: Triglycerides > 130 mg/dL (40) 
Adult  
 >19 years: Triglycerides > 150 mg/dl, LDL-C > 100 mg/dl, HDL-C <40 (males) or <50 
(women) based on Adult Treatment Panel guidelines (108). 





 Fasting plasma glucose level and HbA1c% (glycosylated hemoglobin) were measured at 1, 18, 
and 30 month time points, as shown in Figure 1.  
Biochemical analysis of HbA1c% was performed in Children’s National laboratory using a DCA 
Vantage Analyzer (Siemens Medical Solutions USA, Inc, Malvern PA). Participants had 1 mL of 
blood collected in an EDTA lavender top tube for point-of-care testing. The blood was then 
drawn into a capillary holder (0.1 mL) and placed in the buffer tray of the analyzer to activate the 
chemical reaction. This chemical reaction involves formation of a Schiff base compound that 
exists in equilibrium with glucose and hemoglobin A. Some of the Schiff base then undergoes an 
Amadori rearrangement to form HbA1c, which reflects the concentration of glucose present in 
the body over a period of time, based on the 60 day half-life of erythrocytes.  The percent HbA1c 
of the sample is displayed on the analyzer, and may range from 2.5% to 14.0%. 
Prevalence of impaired glucose tolerance was determined in the obese and non-obese transplant 
groups, according to the following American Diabetes Association definitions: fasting glucose 
>100 mg/dL, HbA1c >5.6%, or requiring insulin or oral hypoglycemic medication (109).  
Metabolic Syndrome  
Transplant patients with MS were defined as those who met ≥ 3 of the following 5 criteria: 
abdominal obesity, glucose intolerance, hypertension, low HDL-C (or on lipid-lowering 
medication), elevated triglycerides (or on lipid-lowering medication). 
Myocardial Function and Strain   
An echocardiogram was obtained at 1, 18 and 30 months post-transplant. The echocardiograms 
were performed by a single pediatric Diagnostic Medical Research Sonographer and 
measurements performed by a pediatric cardiologist, according to American Society of 





iE33 xMatrix DS Ultrasound System (Philips North America Corporation, Andover, MA). 
Echocardiogram were analyzed using a Syngo Velocity Vector Imaging (Siemens, Germany) by 
a pediatric cardiologist blinded to the subject’s clinical information. Standard echo parameters 
included LV mass indexed to height
2.7
,  FS by standard M-mode method, and EF by Simpson’s 
method.  In addition to these standard echo measures of LV size and function, measures of 
myocardial strain were assessed using speckle tracking analysis. Endocardial tracings of the left 
ventricle were performed of both the parasternal short-axis and apical four-chamber views for 
each subject. Parasternal short-axis tracings were conducted at the level of the papillary muscles. 
Myocardial strain (%) was assessed in the circumferential (short-axis measurement) and 
longitudinal (long-axis measurement) directions. Strain was calculated by measuring the end 
systolic distance between two speckles of tracked endocardium minus the original distance 
divided by the original distance. Because the myocardium contracts in the longitudinal and 
circumferential directions during systole, these values are negative percentages, and more 
negative values indicate better cardiac contractility. Measures of longitudinal and circumferential 
strain were compared between the obese and non-obese transplant groups and a healthy control 
group. In study participants who had a pre-transplant echo performed for clinical purposes within 
one year prior to transplant, echo and strain parameters were retrospectively analyzed and 
included for comparison. Changes in echo and strain parameters over time were assessed 
longitudinally, and determinants of LVH and strain were analyzed by multivariate Generalized 
Estimating Equation (GEE) regression analyses.   
CIMT  
CIMT was obtained at 1, 18 and 30 months post-transplant. B-mode ultrasound imaging of the 





performed according to a standard protocol by a single pediatric Diagnostic Medical Research 
Sonographer.  The same instrument was used for all study participants: iE33 xMatrix DS 
Ultrasound System (Philips North America Corporation, Andover, MA).  The CIMT protocol 
was as follows: 
1) Patient is placed in the supine position with his/her neck slightly hyperextended, and 
rotated 30-45 degrees to the contralateral side. 
2) Label screen Right Carotid.  Scan the right carotid bifurcation in short axis. 
3) Scan right carotid bifurcation in long axis.  All efforts should be made to identify the 
optimal angle of orientation, visualizing both the internal and external arteries 
simultaneously. 
4) Repeat long axis imaging of the carotid bifurcation in color flow to demonstrate any 
areas of plaque or flow disturbance. 
5) Identify the angle of optimal image and thickest intimal interfaces on the far walls. 
6) M-mode of common carotid artery 1 cm proximal to the bulb, (label and store image). 
7) PW Doppler internal carotid artery to confirm correct vessel identification, (label and 
store image). 
8) Image common carotid artery distal far wall, (label and store image real time and freeze 
frame). 
9) Image bulb far wall, (label and store image real time and freeze frame) 
10)  Image internal carotid artery proximal far wall, (label and store image real time and 
freeze frame). 






Intima-media thickness of the distal, mid, and proximal segments of right and left common 
carotid arteries and carotid bulbs was then measured by a single pediatric cardiologist blinded to 
the patient’s clinical information.  A composite of the 8 measurements was used to represent the 
individual’s CIMT. CIMT parameters were compared between the A-A and non-A-A as well as 
the obese and non-obese transplant groups and the healthy control group. Change in CIMT over 
time was also assessed longitudinally.   
D. Leptin  
Fasting morning leptin levels were measured in a subset of the transplant group (n=27) between 1-
30 months post-transplant. As this test is not part of standard care for transplant recipients, the 
sample for this analysis was collected from the laboratory by the investigators if blood was left over 
from the routine sample drawn at the transplant patient’s clinic visit. For this reason, blood samples 
were not available for every subject at every time point. From the blood sample collected, 0.5 mL of 
plasma was centrifuged, refrigerated, and used for analysis of leptin using enzyme-linked 
immunosorbent assay (ELISA). Studies have validated ELISA as an accurate method for 
determining plasma leptin levels (111) . 
E. Historical data collection 
Historical information was obtained from the participant’s electronic medical record at 
Children’s National.  This included the following information: 
 Medical history and comorbidities 
 Duration and modality of dialysis 
 Calcium x phosphorus product prior to transplant 
 Parathyroid hormone level at time of transplant 
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Statistical analysis was performed using STATA 14.0 software.   
Sample size and power calculations 
Bivariate: Sample size and power calculations for strain are based on our previous study of 
myocardial strain in a pediatric hemodialysis population, where a significant difference in 
longitudinal strain rate between the carnitine treated group (n=9) and the control group (n=8) 
was identified (mean and SD: -1.48+0.33 vs. -1.91+0.36, p=0.017)(112).  Sample size 
calculations for CIMT are based on prior publications in the literature, which demonstrate a 0.03-
0.04 mm difference in CIMT as significant (36, 82), and the SD of CIMT in prior studies of 
healthy children is 0.03-0.04 (113).  
Using STATA 14.0 software, it was determined that a minimum sample size of 24 transplant 
recipients (14 lean transplant and 10 obese transplant) and 24 healthy controls will provide >80% 
power to detect a significant difference in CIMT and myocardial strain between groups, 
assuming a two tailed t-test type 1 error of 5%.  
Multivariate: In addition, power analysis for multivariate regression modeling was calculated for 
strain and CIMT. Based on the published literature, regression models testing associations of 
obesity with strain and CIMT are estimated to have an expected R
2
 value of 0.55 (114, 115) . 
Assuming that obesity contributes 0.1 to the R
2
, a minimum of 38 observations for strain and 
CIMT respectively will provide 80% power to detect significant associations for a regression 
model with 6 predictor variables.  Assuming an average of 3 observations per patient, our 
minimum sample size of 24 transplant patients (a minimum of 72 observations) will be more 





Overall power and sample size: Therefore, considering the above calculations, our goal was to 
enroll a minimum of 24 transplant recipients and 24 healthy control patients to achieve adequate 
power for both the bivariate and multivariate analyses.  Given the longitudinal nature of the 
study and the inherent risk of missed visits, drop outs, or losses to follow-up over 30 months 
duration, we allowed for enrollment of up to 42 transplant participants to ensure that our 
minimum target sample size of 24 transplant patients would be met each time point.  
Univariate analysis 
Determine the prevalence of the following morbidities in the transplant group at pre-transplant, 
1, 18, and 30 months post-transplant: 
• Obesity (by WC, BMI, and WHr) 
• Dyslipidemia (high LDL-C, high TG, low HDL-C) 
• Impaired glucose tolerance (HbA1c%>5.6 or fasting glucose >100) 
• Hypertension (requiring antihypertensive medication)  
• Uncontrolled hypertension (BP > 95th %ile for age-sex-height) 
• Metabolic Syndrome (meet ≥ 3 of the following 5 criteria: 1) glucose intolerance, 
2) hypertension, 3) low HDL-C, 4) high triglycerides, or 5) abdominal obesity 
(defined by WC and/or WHr methods) 
• Abnormal CV parameters (Left ventricular hypertrophy, impaired myocardial 
strain, increased CIMT) 
Bivariate analysis 
1. Comparison of anthropometric measures, blood pressure, and CV outcomes between 
groups by  Student’s t-test or Wilcoxon rank-sum 





• Obese vs. lean transplant (LVH, strain, CIMT) 
• A-A vs. non-A-A transplant (CIMT) 
• Time point comparisons: Pre-transplant*, 1, 18 and 30 months post-transplant 
*note that only anthropometrics, biochemical parameters, echo and strain 
parameters were retrospectively available at the pre-transplant time point. 
Measures of WC, WHr, and CIMT were not available pre-transplant. 
2.  Chi-square test of proportions to assess relationship of pre-transplant hyperparathyroidism 
with high CIMT at 1 month post-transplant.   The purpose of this comparison is to assess effect 
of abnormal pre-transplant bone and mineral metabolism on CIMT immediately post-transplant.  
3. Student’s t-test to assess difference in mean leptin levels between lean and obese (by BMI, 
WHr, and WC) transplant groups.   
4. ROC curve analysis to compare ability of BMI, WC, and WHr to detect a composite adverse 
CV outcome.   The adverse CV outcome was defined as the presence of at least 3 of the 
following 5 criteria: 1) LVH (66), 2) high CIMT (>95
th 
percentile for race, based on healthy 
control data), 3) high myocardial strain (>95
th
 percentile, based on healthy control data), 4) 
dyslipidemia, and/or 5) hypertension. The measures of diagnostic accuracy (AUC) were used to 
compare ability of WHr, WC, and BMI to detect obesity-related adverse CV outcome in the 
transplant population. Sensitivity and specificity are also reported 
Multivariate analysis 
 GEE multivariate regression was used to determine associations of obesity (by 
BMI, WC, and WHr) and MS with adverse CV outcomes (LVH, impaired 
longitudinal and circumferential strain, increased CIMT) in the transplant 





examine associations between predictors and outcomes, accounting for within-
subject correlation between the repeated measures over time.  The equation for 
GEE is shown below, where i represents subject, j represents time, βk is the 
regression parameter, and Vi is the variance structure: 
 
 Collinearity Analysis. Prior to constructing the GEE regression models, a 
correlation matrix was run to evaluate for correlations between the independent 
variables.  Variables that were found to be highly correlated were removed/not 
included together in the same GEE models.  Due to high correlation between 
BMI-obesity, WC-obesity, WHr-obesity and MS variables, 4 separate GEE 
regression models were created to examine associations each type of obesity and 
MS with each adverse CV outcome (Left ventricular hypertrophy, impaired 
myocardial strain, increased CIMT). 
 Selection of the “correlation structure” for the GEE regression by QIC.  
The equation for QIC is show below:  
 
Based on the study design, two possible GEE correlation structure options were 
“exchangeable” or unstructured”.  To evaluate these options, the Qasi-likelihood 
under Independence model Criterion (QIC) values for the exchangeable and 





model (593.8 vs 594.4), where myocardial longitudinal strain was the dependent 
variable. Given no significant difference between the two options, the 
unstructured correlation structure was ultimately selected as the better choice 
because it does not place any assumptions on the within-subject correlation over 
time, whereas the exchangeable structure assumes that the within-subject 
correlation does not vary but remains constant. 
  Selection of the best regression model by QIC. GEE regression was performed 
starting with a full model that included all the independent variables of interest 
(n=15).  The QIC for the full model was generated.  Then, a stepwise process was 
used, whereby a single independent variable was removed from the model, and 
then the new model run.  At each step, the variable with the highest p-value was 
removed from the model, and QIC value generated for each model, until only 
independent variables with significant p-values (<0.05) remained.  Then, the best 
and final GEE model was selected based on the model that had the lowest QIC 
value.  Interaction terms were explored after selection of the final model. 
 Multivariate Linear and Logistic regression. In addition to the GEE regression 
described above,  linear and logistic regression models were used to evaluate for 
associations of pre-transplant variables (duration of dialysis prior to transplant, 
exposure to hemodialysis prior to transplant, history of renal replacement therapy 
prior to transplant vs. pre-emptive, pre-transplant hyperparathyroidism) with CV 
outcomes (longitudinal and circumferential strain, and  high CIMT) at pre-
transplant and 1 month post-transplant time points individually. These potential 





be likely to influence CV outcomes only during pre-transplant or at 1 month post-
transplant, and would not be expected to continue to influence CV outcomes into 
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Obesity and metabolic syndrome (MS) are common after kidney transplantation, but their 
contribution to adverse cardiovascular (CV) outcomes in children are not well known. A 
prospective, controlled, longitudinal cohort study was conducted to investigate effects of obesity 
and MS on left ventricular hypertrophy (LVH) and myocardial strain in pediatric kidney 
transplant recipients. Transplant recipients (n=42) had anthropometrics (BMI, waist 
circumference, waist-to-height ratio), biochemical parameters (fasting glucose, lipid panel, 
HbA1c%), and echocardiogram with speckle tracking analysis for strain measured at 1, 18, and 
30 months post-transplant. Additionally, 35 pre-transplant echocardiograms were analyzed 
retrospectively.  Healthy children (n=24) served as controls. Waist-to-height ratio detected  
abdominal obesity in 46% of transplant patients, whereas only 8.1% were identified as obese by 
waist circumference. Ejection fraction and fractional shortening of the transplant group were 
normal and similar to controls. Prevalence of LVH was 35.2%, 17.1%, and 35.5% at 1, 18, and 
30 months. Longitudinal strain of transplant was worse than controls at all time points (p<0.001). 
Hemodialysis independently predicted 21% worse longitudinal strain compared with peritoneal 
or no dialysis during the pre-transplant period (p=0.04). After transplant, obesity, MS, and 
systolic hypertension predicted increased odds of LVH (p<0.04).  Worse longitudinal strain was 
independently associated with obesity, hypertension, combination of MS with elevated LDL-C-C 
cholesterol, and steroid therapy (p<0.03), while higher eGFR conferred a protective effect 
(p<0.001). Obesity and MS adversely affect CV outcomes after transplant. Further studies are 
needed to investigate speckle tracking echocardiography as a tool for early detection of 







Cardiovascular (CV) disease is the second leading cause of morbidity and mortality amongst 
children after kidney transplant (2). The development of obesity and metabolic syndrome (MS) 
are common in pediatric kidney transplant recipients, but their contribution to adverse CV 
outcomes is not well defined in this population. In transplant recipients, typical risk factors for 
MS, such as excess intake of processed foods and physical inactivity, converge with transplant 
medication-induced effects of dyslipidemia, glucose intolerance, and hypertension to create a 
hybridized version of MS unique to this population, the long-term effects of which are not well 
known (116, 117). Effects of obesity and MS on CV function can be present during childhood, 
but the signs are likely to be subtle in the early stages (3, 4).  As major CV events are rare in 
children, abnormalities may not become apparent until they are in late stages, when the 
opportunity for early intervention has been missed.  The detection of overt abnormalities such as 
alteration in measures of systolic left ventricular function by echocardiography, including 
ejection fraction (EF) or fractional shortening (FS), are rare in the pediatric population (25). 
Even among children with obesity and MS, EF is typically found to be normal (63).  Evaluation 
of left ventricular mass by traditional echocardiography is also of limited use in detecting CV 
dysfunction in children with end stage renal disease (ESRD), due to the lack of agreement about 
how to accurately define left ventricular hypertrophy (LVH) in young children, underestimation 
of LVH in overweight patients, and lack of reliability in fluid overloaded patients(65, 67).  
Speckle tracking echocardiography, a newer non-invasive and highly sensitive imaging 
technique, may offer the opportunity for early detection of subclinical CV disease.  Speckle 





evaluation of patients with kidney disease (118).  In a recent study of adult hemodialysis patients 
with preserved EF, myocardial strain was a strong independent predictor of mortality, supporting 
the utility of speckle tracking echocardiography in identifying early subclinical CV risk (102).  
Little is known about the myocardial strain of pediatric kidney transplant recipients. This is the 
first longitudinal study to investigate the effects of obesity and metabolic syndrome on 
myocardial strain in pediatric kidney transplant recipients. 
Methods 
Study Design and Population 
A prospective, controlled, longitudinal cohort study was conducted to investigate the effects of 
obesity and metabolic syndrome on CV outcomes including assessment of myocardial function 
by speckled tracking analysis in pediatric kidney transplant recipients. Children who received a 
kidney transplant at Children’s National were eligible to participate in the study. Participants 
(age 3-20 years) were eligible to enroll between 0 and 18 months post-transplant and were 
followed until 30 months post-transplant. Those with estimated glomerular filtration rate (eGFR) 
<60 mL/min/1.73m
2
 , multi-organ transplant, and nephrotic-range proteinuria were excluded.  
Twenty-four healthy children (age 3-20 years) were enrolled as controls.  Approval was obtained 
from the Institutional Review Board (IRB) at Children’s National. Informed consent was 
obtained from all participants and the study was performed in accordance with the Declaration of 
Helsinki. 
Classification of Obesity and MS 
Body Mass Index (BMI) as well as two anthropometric measures of abdominal obesity: waist 
circumference (WC) and waist- to- height ratio (WHr) were measured at all time points. BMI-
obesity was defined as BMI>95
th





defined as WC >95
th
 percentile for age-and-sex (106).  Since children with kidney disease 
commonly have short stature, an additional measure of abdominal obesity indexed to height 
(WHr) was included. WHr-obesity was classified as  >0.539, based on NHANES III data 
according to the method of Kahn et al. (19). All transplant patients had blood pressure and 
biochemical parameters, including fasting glucose, fasting lipid panel, and HbA1c% measured at 
each time point.  MS in transplant patient was defined as those who met ≥ 3 out of the following 
5 criteria: 1) abdominal obesity, 2) glucose intolerance, 3) hypertension (controlled or 
uncontrolled), 4) low HDL-C cholesterol, 5) elevated triglycerides.  Glucose intolerance was 
defined as HbA1c%>5.6% or fasting glucose>100 mg/dL or on glucose-lowering medication 
(109).  Hypertension was defined by use of antihypertensive therapy;  uncontrolled hypertension 
was defined as having a systolic or diastolic blood pressure z score corresponding to  >95
th
 
percentile for age, sex, and height for children 2-18 years old (107) and >130/85 mm Hg for 
those >18 years old. Cut points for low HDL-C and high triglycerides were defined according to 
2011 pediatric guidelines (40) for study participants age 3-19, and by Adult Treatment Panel III 
criteria (108) for >19 years of age.  
Echocardiographic Methods 
An echocardiogram (echo) was obtained at 1, 18 and 30 months post-transplant. The echos were 
performed by a single pediatric sonographer using the iE33 xMatrix DS Ultrasound System 
(Philips North America Corporation, Andover, MA), according to American Society of 
Echocardiography standards (110).  In addition, 35 of the 40 transplant patients had pre-
transplant echos that were analyzed retrospectively.  Echos were analyzed using Syngo Velocity 
Vector Imaging (Siemens, Germany) by a pediatric cardiologist blinded to the subject’s clinical 








), FS by standard M-mode method, and EF by Simpson’s method.  In addition, 
myocardial strain (%) was assessed in the circumferential (short-axis) and longitudinal (long-
axis) directions by speckle tracking analysis. Strain was calculated by measuring the end systolic 
distance between two speckles of tracked endocardium minus the original distance divided by 
the original distance. Because the myocardium contracts in the longitudinal and circumferential 
directions during systole, these values are negative percentages, and more negative values 





according to the age-specific percentiles of Khoury et al. (66). Echo and strain parameters of the 
transplant group were compared to controls, and changes over time were assessed longitudinally.  
Statistical Analysis 
All statistical analyses were conducted using Stata 14.0 (StataCorp LP, College Station, TX). 
Categorical variables were compared by Chi-square analysis. Student’s t-test was used to 
compare means of normally distributed continuous variables between groups and Wilcoxon 
rank-sum was used for continuous non-normally distributed variables. Mean+SEM and median 
(IQR) are reported for continuous variables.  
Pre-transplant determinants of LVH and strain   
In order to understand the differential effects of pre-transplant exposures, we analyzed effects of 
type and duration of renal replacement modalities on LVH and strain in the pre-transplant period 
and at 1 month post-transplant. Multivariate linear and logistic regression models were used to 
evaluate for associations of pre-transplant independent variables (type and duration of dialysis, 
pre-emptive transplant vs. dialysis) with LVH and strain prior to transplant and at 1 month post-
transplant.  





Generalized estimating equation (GEE) multivariate regression with unstructured correlation was 
used to conduct longitudinal analysis of determinants of LVH and strain post-transplant. GEE 
regression accounts for the within-patient correlation inherent to longitudinal serial data, and is 
robust to missing data (120). Due to collinearity between the three anthropometric measures of 
obesity and MS, four separate models (1. BMI-obese, 2.WC-obese, 3.WHr-obese, and 4. MS) 
were created to evaluate associations of each with the CV outcome of interest (LVH, 
longitudinal strain, and circumferential strain).  The additional independent variables included in 
each full GEE regression model were: age, sex, race, hypertension, glucose intolerance, low 
HDL-C cholesterol, high triglycerides and, LDL-C cholesterol level, steroid dose, high SBP or 
DBP z score, and eGFR.  Quasi-likelihood under the independence model information criterion 
(QIC) measure was used to select the best fit model in a stepwise procedure.  
Results 
Study population 
Demographics and characteristics of the transplant and control groups are summarized in Table 
1. The study group was comprised of 42 pediatric kidney transplant recipients who were 12.1+ 
0.7 years of age and 50% A-A, with a mean eGFR of 94.4+4.4 mL/min/1.73m
2
 at 1 month post-
transplant. All transplant recipients were maintained on standard immunosuppression therapy 
with Tacrolimus and Mycophenolate Mofetil, and approximately half were receiving steroid 
therapy in addition.  Controls comprised of24 healthy children of similar age and race 
distribution.  
Of 42 transplant patients, two were excluded from cardiac assessment due to discovery of a 





100 prospective echos were performed in the remaining 40 patients over the 1 to 30 months post-
transplant.  A total of 24 echos were performed in the 24 control participants on one occasion. 
Prevalence of Obesity and Cardiometabolic Abnormalities 
The prevalence of metabolic and CV morbidities in transplant patients at each time point are 
reported in Table 2. The prevalence of obesity as detected by WHr was significantly higher than 
by WC alone at 1, 18, and 30 months post-transplant (p=0.01, 0.0002, and 0.05 respectively). 
Approximately one-third of patients had post-transplant MS. Hypertension was highly prevalent 
pre- and post-transplant. Prevalence of hypertriglyceridemia was higher prior to transplant 
(79.2%), compared with 35.9%, 24.3%, and 29.4% prevalence at 1, 18, and 30 months post-
transplant (p<0.001). The triglyceride to HDL-C (TG/HDL-C) ratio, an indicator of  atherogenic 
LDL-C particle composition, was significantly higher in transplant recipients with MS (mean 
TG/HDL-C+SEM 4.2+0.8, 4.9+1.2, and 4.0+0.9) compared to those without MS (2.1+0.3, 
1.6+0.2, and 1.9+0.3) at 1, 18, and 30 months post-transplant, p=0.009, p=0.006, and p=0.02, 
respectively. Details of biochemical indicators of transplant recipients at each time point are 
summarized in Table 3. 
Comparison of CV parameters: transplant and controls 
Standard echo parameters 
EF and FS of transplant patients were within normal range at all time points. Mean EF was 
62.4+0.5%, 64.7+0.7%, 63.9+0.5% and 64.1+0.6% (normal 55-70%), and FS was 35.5+0.9%, 
37.0+0.8%, 37.4+0.9%, 38.0+0.8% (normal 28-40%) at pre-transplant, 1 month, 18 months, and 
30 months post-transplant. EF and FS of transplant patients were similar to that of controls, 
(64.1+0.5% and 34.8+0.9%, respectively). LVM/height
2.7
 (median, IQR) of transplant recipients 





43.2 at 1 month, 33.0, IQR 29.7-39.0 at 18 months, and 35.8, IQR 28.2-42.6 at 30 months post-
transplant vs. 29.7,  IQR 26.1-32.1 g/m
2.7
 in controls, p<0.03).  
Myocardial strain 
All transplant recipients, both lean and obese, had worse longitudinal strain than controls at all 
time points, p< 0.001(Figure 1). Circumferential strain of transplant recipients did not differ 
significantly from controls.  
Changes in CV parameters of transplant recipients over time 
LVH was present in 37.1%, 35.2%, 17.1%, and 35.5% at pre-transplant, 1, 18, and 30 months 
post-transplant, respectively (Table 2).  Mean longitudinal strain was -17.4+0.67 pre- transplant, 
improved to -19.7+0.59 and -19.9+0.44 at 1 and 18 months post-transplant (p=0.01 and 0.002 vs. 
pre-transplant), but did not statistically differ at 30 months post-transplant (-18.7+0.44). Mean 
circumferential strain was -22.3+0.76 pre-transplant and improved to -25.0+0.70, -25.5+0.58, 
and -25.7+0.61 (p=0.01, 0.001, and 0.001, respectively), though did not differ from controls.  
Determinants of LVH and myocardial strain  
Pre-transplant: Adjusted multivariate linear regression indicated that chronic hemodialysis (HD) 
was the key significant independent predictor of worse longitudinal strain during the pre-
transplant period. After adjusting for age, sex, race, hypertension, obesity, and 
hyperparathyroidism. HD was associated with a 4.0+1.9 impairment in longitudinal strain 
compared with those who received a pre-emptive transplant or were on PD (p=0.04).  No 
significant associations between type or duration of renal replacement therapy with pre-
transplant LVH or circumferential strain were identified, after adjusting for age, sex, race, 





1 month post-transplant: By 1 month post-transplant, history of receiving HD no longer affected 
longitudinal strain (p=0.18).  Obesity became the key independent predictor of worse 
longitudinal strain at 1 month post-transplant. Obesity was independently associated with a 
3.6+1.6 impairment in longitudinal strain at 1 month post-transplant (p=0.04). In addition, 
obesity was an independent predictor of increased odds of LVH at 1 month post-transplant (OR 
3.8+1.8, p=0.3). No significant associations were identified between pre-transplant type or 
duration of renal replacement therapy with circumferential strain at 1 month. 
Post-transplant (longitudinal analysis over 1-30 months)   
The results of the adjusted longitudinal GEE analysis as classified by the four regression models 
(BMI-obese, WC-obese, WHr-obese, and MS) are summarized in Table 4. 
LVH: BMI-obesity, WHr-obesity, and MS were associated with 3.7+1.9, 2.8+1.3, and 3.5+1.7 
times higher odds of post-transplant LVH, respectively, whereas WC-obesity was not a 
significant predictor. In addition, high SBP z-score was independently associated with higher 
odds of LVH after transplant (OR+SEM= 5.2+3.2, p=0.007, 4.1+2.5, p=0.02, and 3.9+2.4, 
p=0.03, in the BMI, WHr and WC adjusted models, respectively).  
Myocardial strain: BMI-obesity, WHr-obesity, and WC-obesity, were independently associated 
with worse longitudinal strain after transplant (Table 4).  In addition, hypertension was 
independently associated with worse longitudinal strain across all models. Higher eGFR was 
independently associated with improved longitudinal strain across all models. Neither MS 
(p=0.06) nor LDL-C level (p=0.2) were independently associated with longitudinal strain, 
however, there was a significant interaction between MS and LDL-C level, suggesting that the 





strain, p=0.01 (Figure 2). In addition, there a significant interaction between WHr-Obesity and 
LDL-C cholesterol produced worse longitudinal strain, p=0.0001. 
No significant associations between obesity, MS, or other determinants with circumferential 
strain were identified in the multivariate regression.  
Discussion 
The results of this prospective longitudinal study indicate that obesity and MS are highly 
prevalent and significantly impact CV outcomes in pediatric kidney transplant recipients. BMI-
obesity, WHr-obesity, and MS were significant predictors of increased odds of LVH post-
transplant, whereas WC-obesity was not significant. In addition, systolic hypertension was a 
significant contributor to post-transplant LVH.  Speckle tracking echocardiography was able to 
detect pre and post-transplant impairment in myocardial strain that was not evident by standard 
measures of left ventricular function, such as EF and FS.  
In our cohort, EF and FS of the study group were maintained within normal range and were 
similar to controls across all time points. However despite the appearance of normal myocardial 
function by EF and FS, impaired subclinical CV function was revealed by the longitudinal strain 
of the study participants, which was significantly worse than the controls at all time points. 
These findings are in agreement with those of a previous study that reported changes in 
myocardial strain despite preserved EF in children with end stage renal disease (19 dialysis 
patients, 17 transplant recipients, and 33 age-matched controls) (104). Similar to the findings of 
Van Huis, et al.(104), the myocardial dysfunction observed in our transplant cohort was 
characterized by impaired strain in the longitudinal direction, while circumferential strain did not 
differ from controls.   The reasons for the lack of changes in circumferential strain may be 





reproducible than circumferential strain, as the short-axis circumferential motion is technically 
more difficult to track than the longitudinal base-to-apex contraction of the myocardium (121). 
Additionally, longitudinal strain is highly sensitive for detecting myocardial disease early in the 
progression, whereas circumferential strain may remain normal or show exaggerated 
compensation for preserving left ventricular systolic performance (122).  Therefore, longitudinal 
strain appears to be a more sensitive and accurate indicator of early signs of CV disease in 
children.   
Ours is the first study to investigate the effects of obesity and MS on myocardial strain in 
pediatric transplant recipients. Consistent with prior reports in the literature, the prevalence of 
obesity in our cohort (as measured by BMI) approximately doubled after transplantation, from 
14.2% pre-transplant to 35.1% at 18 months post-transplant (25).  As abdominal obesity 
measured by WC or WHr is more strongly associated with high metabolic and CV risk than is 
high BMI in the general pediatric population (19-21), we also examined both of these parameters 
in our transplant cohort. While the prevalence of abdominal obesity appeared low (8.1%) when 
assessed by WC-for-age percentiles, it increased to 46% when measured by WHr (Table 2).  
Given the predominance of short stature amongst children with ESRD, our results suggest that 
evaluating abdominal circumference without correcting for height may underestimate the true 
prevalence of visceral obesity in this population.  The reported prevalence of post-transplant MS 
in the pediatric literature is variable (ranging from 14.2%-68%), due in part to differing criteria 
used for definition of MS (7, 8).  In our study, approximately one-third of the transplant 
recipients had MS, where abdominal obesity was required for the diagnosis.  
We examined the effects of pre-transplant variables affecting LVH and strain outcomes.  Chronic 





transplant period, after adjusting for other pre-transplant factors, including hypertension and 
obesity. HD was associated with a 21% worsening in longitudinal strain, compared to those who 
received a pre-emptive transplant or were on peritoneal dialysis prior to transplant.  Evidence 
indicates that children receiving HD are subject to ischemic cardiac injury caused by myocardial 
stunning (123).  This data substantiates the notion that subclinical CV impairment is occurring in 
children receiving HD, and this should be considered when choosing renal replacement modality.  
Obesity was not a significant predictor of strain pre-transplant, but emerged as the key player 
starting as early as 1 month post-transplant.  
Obesity was a key independent predictor of worse longitudinal strain over 1-30 months post-
transplant (Table 4).  Hypertension also conferred to significant risk for worse longitudinal 
strain. The only variable in the model associated with significant improvement in longitudinal 
strain was higher eGFR, suggesting that better kidney function confers a protective effect with 
respect to myocardial function after transplant.  
The association of MS with longitudinal strain was not significant (p=0.06) in the adjusted 
regression, however there was a significant interaction between MS and higher LDL-C level 
resulting in impaired longitudinal strain (Figure 2). A similar interaction was noted between 
abdominal WHr-obesity and LDL-C level.  An association of impaired longitudinal strain with 
increased serum LDL-C level as well as with myocardial cholesterol concentration has been 
previously demonstrated in an animal model (124).  A possible mechanism for the adverse effect 
of LDL-C cholesterol on strain may be related to cardiac oxidative stress caused by accumulation 
of cholesterol in the myocardium.  Although LDL-C cholesterol is not a component of the 
traditional definition of MS, it appears that the combination of MS with higher LDL-C produces 





this phenomenon may be explained in part by differences in the specific nature of the LDL-C 
particles found in children with abdominal obesity compared to those without abdominal obesity.  
Children with abdominal obesity are prone to generate smaller, denser, more atherogenic LDL-C 
particles, the presence of which can indicated by an elevated TG/HDL-C ratio of >3.0 (125, 
126).  A longitudinal cohort study demonstrated that presence of high TG/HDL-C ratio at age 12 
was able to predict the occurrence of adverse CV events 3-4 decades later in life (127). In our 
transplant cohort, children with MS were noted to have an elevated TG/HDL-C ratio (>3.0), 
while those without MS had normal TG/HDL-C ratio.  Further studies are needed to investigate 
how the combination of MS and elevated LDL-C impacts CV outcomes of pediatric transplant 
recipients, in whom the effects of MS may not conform to the classical definition.   
There were several limitations to our study.  Although the longitudinal study design was 
prospective over time post-transplant, the pre-transplant echocardiograms were obtained from 
the medical record and retrospectively analyzed. As there were no pre-transplant measures of 
WC available, we were unable to assess the prevalence of abdominal obesity or MS.  Although 
the distribution of male and female gender was different between the transplant and control 
group, gender was not significantly associated with any of the CV outcomes across all regression 
models.  
In conclusion, pediatric kidney transplant recipients have a high prevalence of obesity and MS.  
WHr identifies abdominal obesity in a greater proportion of these patients compared to WC, due 
to the prevalence of short stature in this population.  Additionally these patients have CV 
abnormalities, which include LVH and impaired myocardial strain. Prior to transplant, exposure 
to HD results in worsening of  longitudinal strain compared with children receiving peritoneal 





present in children and is exacerbated by obesity, hypertension, and the combination of MS with 
atherogenic LDL-C cholesterol, highlighting the importance of efforts to manage weight, control 
blood pressure, and treat dyslipidemia. Higher eGFR appears to confer a protective effect on 
myocardial strain. Further studies are needed to determine if speckle tracking echocardiography 
can serve as a useful clinical tool to provide a means of detection of subclinical myocardial 






Tables and Figures  
Table 1. Demographics and clinical characteristics of the transplant and control groups 






Transplant vs  
Controls 
Age (years) 12.1+ 0.7 11.1 + 0.5 0.31 
Race (%) 50% A-A 58% A-A 0.53 
Sex   (%) 62% male 25% male 0.004* 









Duration dialysis (months) 
Hemodialysis 
Peritoneal Dialysis 







1 month  
18 months  
30 months  





Steroid protocol  
1 month  
18 months  






Steroid dose of those on 
steroid therapy 
(mg/kg/day)  
1 month  
18 months  
30 months  













Table 2. Prevalence of metabolic and CV morbidities in transplant group over time  

















































































































































NS= not significant 
*significant difference between pre-transplant and 1 month post-transplant by Chi-square 
**significant difference between pre-transplant and 18 months post-transplant by Chi-square 







Table 3. Biochemical indicators of transplant recipients at each time point 















































































































































Intact PTH ( within 30 






NA NA NA 
 
#significant difference between transplant time points, p<0.05 by Student’s t-test 












               
Longitudinal      
Strain (%) 
 
 OR+ SEM 
[95%CI] 
p value  β + SEM [95%CI] p value 
Model I. 
BMI-Obese 





0.01*    






 1.5 +0.39 [0.78- 2.3] 
 1.4+0.49  [0.43-2.3] 
-0.04+0.01[-.06-.02] 
 

















1.1+0.42   [0.23-1.8] 
1.5+0.46   [0.62-2.4] 
-0.04+0.01[-0.06-.02] 
 





High SBPz  
 
3.5+2.7 [0.8-15.5]        
3.9+2.4 [1.2-13.2] 
 





eGFR   
 
1.6+0.51   [0.63-2.6] 



























n= 100 observations of 40 patients 
**Longitudinal GEE models were created to examine each of the following independent 
variables: BMI-obese, WHr-obese, WC-obese, and MS with CV outcomes LVH and longitudinal 
strain (dependent variables). Additional covariates included in the full model were: age, sex, 
race, hypertension, glucose intolerance, high triglycerides, low HDL-C, LDL-C level, steroid 
dose, high SBP z score, high DBP z score, eGFR. QIC measure was used to select the best-fit 
model in stepwise regression, and the significant associations of the final adjusted model are 
presented above. 






























Figure 1 Caption: *Longitudinal strain of all transplants (Tx) both lean and obese, was 
worse than controls at all time points.  WC was not measured pre-transplant, therefore no 



























Interaction between MS and High LDL-C Predicts 
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Figure 2 Caption: There was a significant interaction between MS and LDL-C level, indicating 
the combination of these variables produces a synergistic effect associated with worse 
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Early signs of subclinical cardiovascular (CV) dysfunction can be detected by ultrasound for 
carotid intima-media thickness (CIMT). Although African Americans (A-A) are at high risk for 
CV disease, CIMT of A-A kidney transplant recipients has not been previously 
investigated.  The aim of this prospective, controlled, longitudinal study was to investigate 
determinants of CIMT in a multi-racial pediatric kidney transplant population, with a focus on 
A-A. Transplant recipients (n=42) had BMI, waist-to-height ratio, fasting glucose, lipid panel, 
HbA1c%, and CIMT measured at 1, 18, and 30 months post-transplant.  Twenty-four healthy 
children (14 A-A) served as controls.  CIMT of A-A transplant (0.49, 0.49 and 0.48mm) was 
higher than non-AA transplant (0.43, 0.44, and 0.44mm) at 1, 18, and 30 months and higher than 
A-A controls (0.47mm).  Hyperparathyroidism prior to transplant predicted high CIMT-for-race. 
A-A race was associated with 10% higher CIMT vs. non-A-A transplant.  Metabolic syndrome 
was associated with 0.03+0.01mm increased in CIMT among A-A transplant recipients only.  In 
conclusion, A-A kidney transplant recipients have increased CIMT.  Metabolic syndrome 
disproportionately affects CIMT of A-A children post-transplant. Identification of subclinical 
CV damage, detected by CIMT, may provide an opportunity for early detection of CV risk in this 
vulnerable population. 










The effects of obesity and metabolic syndrome (MS) on cardiovascular (CV) function are known 
to begin during childhood, but the clinical signs and symptoms typically do not manifest until 
adulthood.  Autopsy studies have identified fatty streaks and atherosclerotic lesions, attributable 
to obesity and MS, in the arteries of children and young adults who died of accidental causes (3, 
4).  As major CV events are rare in children, abnormalities may not become apparent until they 
are in late stages, thus the opportunity for early intervention is missed.  In recent years, non-
invasive imaging techniques have become available for the evaluation of carotid intima-media 
thickness (CIMT), which may provide an early and sensitive marker of subclinical CV 
dysfunction.  Non-invasive ultrasound imaging of the carotid arteries is used to demonstrate the 
status of the intima-media thickness of the vessel and serves as a reproducible surrogate marker for 
early atherosclerosis (78).  Prospective studies have demonstrated that an increase in CIMT is 
associated with an increase in the relative risk for stroke and myocardial infarction in the general 
adult population (79, 80).  Increased CIMT has also been found to be associated with MS and its 
components (obesity, hyperlipidemia, hypertension, glucose intolerance) in the pediatric 
population (81). In pediatric kidney transplant recipients, traditional risk factors for MS, such as 
excess caloric intake and physical inactivity, are compounded by transplant medication-induced 
effects of dyslipidemia, glucose intolerance, and hypertension to create a hybridized version of 
MS unique to this population. Although obesity, and MS are common post-transplant 
complications (2), data is lacking with regard to their effects on CIMT in this high risk 
population.  Prior studies investigating CIMT in pediatric kidney transplant recipients have been 





populations, and yielded conflicting results (89, 90, 92). In addition, despite the known higher 
risks for metabolic morbidities, CV and kidney disease among individuals of African descent 
(13, 48, 53, 54), no prior studies have focused on the CIMT of pediatric kidney transplant 
recipients of African ancestry.   
The aim of this prospective, controlled, longitudinal study was to investigate the effects of MS 
on CIMT in a multi-racial pediatric kidney transplant population, with a focus on African 




Study Design and Population 
A prospective, controlled, longitudinal cohort study was conducted to investigate the effects of 
MS on CIMT in A-A and non A-A pediatric kidney transplant recipients. Children who received 
a kidney transplant at Children’s National Health System (CHNS) in Washington DC, age 3-20 
years, were eligible to participate in the study. Those with estimated glomerular filtration rate 
(eGFR) <60 mL/min/1.73m
2
, multi-organ transplant, and nephrotic-range proteinuria were 
excluded.  Transplant recipients (n=42) enrolled between 0 and 18 months post-transplant and 
were followed until 30 months post-transplant. Healthy children (n=24, of which 14 were AA), 
age 3-20 years, served as controls.  Approval was obtained from the Institutional Review Board 
(IRB) at CNHS. Informed consent was obtained from all participants and the study was 
conducted in accordance with the Helsinki Declaration of 1975.   
Classification of CV Risk Factors 
Obesity and abdominal obesity were assessed by body mass index (BMI) and waist-to- height 
ratio (WHr), respectively. BMI-obesity was defined as BMI>95
th
 percentile (18). WHr-obesity 





Kahn et al. (19). Transplant patients with MS were defined as those who met ≥ 3 of the following 
5 criteria: abdominal obesity, glucose intolerance (109), hypertension (controlled or 
uncontrolled), low HDL-C cholesterol, or elevated triglycerides.  Glucose intolerance was 
defined as HbA1c%>5.6% or fasting glucose>100 mg/dL or on glucose-lowering medication 
(109). Cut points for low HDL-C and high triglycerides were defined according to 2011 
Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents (40) for 
study participants age 3-19, and by the Adult Treatment Panel III criteria (108) for those >19 
years of age.  Hypertension was defined by requirement for antihypertensive therapy.  
Uncontrolled hypertension was defined as having a systolic blood pressure (SBP) or diastolic 
blood pressure (DBP) z score corresponding to >95
th
 percentile for those 2-18 years old (107) 
and >130/85 mm Hg for those >18 years old .  
Measurement of CIMT 
CIMT was measured at 1, 18 and 30 months post-transplant. B-mode ultrasound imaging of the 
arterial far wall segments of the right and left common carotid arteries and carotid bulbs was 
performed according to a standard protocol by a single pediatric Sonographer using aiE33 
xMatrix DS Ultrasound System (Philips North America Corporation, Andover, MA).  Intima-
media thickness of the distal, mid, and proximal segments of right and left common carotid 
arteries and carotid bulbs was then measured by a single pediatric cardiologist blinded to the 
patient’s clinical  information.  A composite of the 8 measurements was used to represent the 
participant’s CIMT. 
Statistical Methods 
Statistical analyses were conducted using Stata 14.0 (StataCorp LP, College Station, TX). 





groups and Wilcoxon rank-sum was used for non-normal continuous variables, with mean+SEM 
and median (IQR) reported. Categorical data were compared by Chi-square analysis.  
Multivariate logistic regression was used to evaluate for associations of pre-transplant variables, 
including duration and modality of dialysis prior to transplant and pre-transplant intact 
parathyroid hormone (iPTH) with high CIMT at 1 month post-transplant, where high CIMT was 
a categorical variable defined as CIMT >95
th
 percentile-for-race (to account for the differences 
between A-A and non A-A), based on our healthy control data.  
Generalized estimating equation (GEE) multivariate regression with unstructured correlation was 
used to evaluate longitudinal association of MS with CIMT. GEE accounts for the within-patient 
correlation inherent to longitudinal serial data, and is robust to missing data (120). Due to the 
non-normal distribution of CIMT in the transplant group, continuous CIMT data were log-
transformed. Independent variables included in the full GEE regression model were: Age, 
gender, race, MS, hypertension, glucose intolerance, hypertriglyceridemia, low HDL-C 
cholesterol, LDL-C cholesterol, steroid therapy,  high SBP z score, high DBP z score, and 
estimated glomerular filtration rate (eGFR).  Quasi-likelihood under the independence model 
information criterion (QIC) measure was used to select the best fit model in a stepwise 
procedure.  Due to the disparate nature of CIMT between AA and non-AA children, the analysis 
was then stratified by race. CIMT of the A-A transplant group was normally distributed, while 





Demographics and characteristics of the transplant and control groups are summarized in Table 





of age and 50% were A-A. All transplant recipients were maintained on standard 
immunosuppression therapy with Tacrolimus and Mycophenolate Mofetil, and approximately 
half were receiving steroid therapy in addition.  Controls were 24 healthy children of similar age 
and race distribution. Of 42 transplant patients, three were unable to tolerate or refused the CIMT 
procedure. A total of 97 CIMT ultrasounds were performed in 39 patients over the 1 to 30 
months post-transplant study period.  All 24 control participants had CIMT measurement done 
on one occasion. 
 
Prevalence of metabolic and CV morbidities post-transplant 
The prevalence of metabolic and CV morbidities within the transplant study group at each time 
point are reported in Table 2, and are summarized below.  
Obesity: The prevalence of BMI-obesity increased from 14.2% pre-transplant to 35.1% at 18 
months post-transplant (p=0.04), and trended down to 27.3% at 30 months post-transplant. The 
prevalence of abdominal obesity by WHr was 41%, 46%, and 36.3% at 1, 18, and 30 months 
post-transplant respectively.  
MS: Approximately one-third of patients had post-transplant MS (33.3%, 29.7%, and 30.3% at 
1, 18, and 30 months, respectively). Prevalence of MS did not change significantly over time 
post-transplant.  
Hypertension: Hypertension was highly prevalent pre-transplant as well as post-transplant.  
Uncontrolled hypertension was less common, with 19.1%, 5.4%, and 12.1% of children affected 
by high SBP at 1, 18, and 30 months post-transplant, and even fewer had uncontrolled DBP 
(11.9%, 2.7%, and 3%, respectively). Prevalence of hypertension did not change significantly 





Dyslipidemia: Dyslipidemia was highly prevalent prior to transplant, with 87.5% of children 
affected by at least one abnormal lipid parameter (high LDL-C, high triglycerides or low HDL-
C).  Approximately half of transplant recipients remained dyslipidemic after transplant (59%, 
46%, 54.5% at 1, 18 and 30 months, respectively). The prevalence of elevated triglycerides was 
significantly higher pre-transplant (79.2%) vs. post-transplant (35.9%, 24.3%, and 29.4%, 
respectively, p<0.001). Elevated LDL-C was also more common pre-transplant vs. 18 months 
post-transplant (37.5% vs. 13.5%), p=0.03 whereas 1 month and 30 months post-transplant 
values were comparable to pre-transplant values.   
CIMT: The prevalence of high CIMT was 29%, 14.7%, and 16.7% at 1, 18, and 30 months post-
transplant, respectively. Within the A-A transplant cohort, the prevalence of high CIMT was 
31.3%, 26.6%, and 22.2%, at 1, 18 and 30 months, respectively. There were no significant 
changes in the prevalence of high CIMT over time post-transplant (Table 2). Similarly, the mean 
and median values of CIMT did not change significantly over time post-transplant (Table 3).  
CIMT of A-A and non A-A transplant and controls 
Within the transplant group, the median CIMT of A-A children (0.49, 0.49 and 0.48 mm) was 
significantly higher than non-AA children (0.43, 0.44, and 0.44 mm) at 1, 18, and 30 months 
post-transplant, respectively (Table 3).  In addition, the mean CIMT of healthy A-A controls was 
higher compared with healthy non A-A controls (0.47 vs 0.44 mm), p=0.02 (see Figure 1).   The 
CIMT of  A-A transplant recipients was greater than that of A-A controls at 1 and 18 month time 
points (0.49 vs. 0.47 mm, p=0.03), see Table 3. The CIMT of the non A-A transplant recipients 
did not differ from the non A-A controls at any time point.  





The mean+SEM pre-transplant iPTH of patients with high CIMT at 1 month post-transplant was 
736.7+ 283.0 pg/mL (95%CI 161.6-1131.9), compared with 337.2+ 75.4 pg/mL (95% CI 184.1-
490.4) in those with normal CIMT. Chi-square analysis demonstrated that pre-transplant 
hyperparathyroidism (iPTH level >600 pg/mL measured within 30 days prior to the transplant 
event) was associated with high CIMT at 1 month post-transplant. Of 27 patients with normal 
iPTH, only 18.5% had high CIMT at 1 month post-transplant, whereas 57.1% of patients with 
high iPTH had high CIMT at 1 month post-transplant (p=0.04), see Figure 2. 
Pre-transplant determinants of CIMT at 1 month post-transplant  
Results of multivariate logistic regression analysis showed that pre-transplant 
hyperparathyroidism was positively associated high CIMT (defined as >95
th
 percentile-for-race, 
based of control data) at 1 month post-transplant (3.8+1.9, p=0.04, pseudo R
2
=0.45). This 
indicates that having high iPTH prior to transplant increases the log odds of having high CIMT 
by 3.8, after adjusting for type and duration of dialysis, dyslipidemia, hypertension, and obesity.  
Determinants of CIMT 1-30 months post-transplant 
In the multivariate longitudinal GEE regression analysis of the entire transplant cohort, A-A race 
was the sole significant predictor of increased CIMT.  The results indicated that A-A race is 
associated with a 10.0%+1.0% higher CIMT compared with non A-A transplant recipients, 
p=0.0001.  Due to the significant impact of A-A race on CIMT, the analysis was stratified by 
race. Results showed that amongst the A-A transplant cohort, the presence of MS was associated 
with a 0.03+0.01 mm increase in CIMT (p=0.002). Amongst the non A-A transplant cohort, 






This study was the first study to investigate CIMT in a cohort of A-A pediatric kidney transplant 
recipients.  Our results reveal that the CIMT of the A-A transplant cohort was significantly 
higher compared with non A-A transplant recipients. The CIMT of A-A controls were also 
higher compared with non A-A controls, necessitating the use of race-specific cut-points for 
CIMT. In addition, the CIMT of the A-A transplant recipients was higher compared to the A-A 
controls, while the CIMT of the non A-A transplant recipients did not differ from their race-
matched controls. We identified pre and post-transplant predictors of race-specific CIMT. Pre-
transplant hyperparathyroidism predicted high CIMT-for-race in the early post-transplant period.  
This finding is in agreement with several other pediatric studies that have identified similar pre-
transplant markers of disordered bone and mineral metabolism, such as high calcium-phosphorus 
product (86, 87) and high cumulative calcitriol dose (90), as predictors of increased CIMT after 
transplant. This finding highlights the importance of good bone and mineral metabolism 
management prior to transplant in order to prevent the formation of vascular calcifications that 
may contribute to increase in CIMT. 
MS was found to be a significant independent predictor of increased CIMT in the A-A transplant 
cohort over 1-30 months post-transplant, but did not affect CIMT of the non A-A children. This 
disproportionate effect of MS on the A-A children occurred, despite the fact that MS was less 
common within the A-A compared to the non A-A transplant cohort (26.8% vs. 35.8% 
prevalence). Thus, our findings indicate that A-A pediatric kidney transplant recipients have 
increased CIMT, which is negatively impacted by MS, whereas the CIMT of non-AA appears 






Given the disparate nature of CIMT outcomes between our A-A and non A-A transplant cohorts, 
further studies are needed to elucidate the etiology and the effects of this phenomenon.  
Individuals of African descent are generally known to carry higher risk for CV disease and 
kidney disease than other races (13, 47-49).  The reasons for these disparities are not completely 
understood, and are likely multifactorial in nature.  Genetic factors are known to play a role, due 
to the strong association of the Apolipoprotein L1 gene (APOL1) with risk of kidney disease in 
individuals of African ancestry. Relationships of APOL1 renal risk variants with increased risk 
of CV disease among those of African descent are also starting to emerge (50, 51). A-A adults, 
including young adults, have higher rates of adverse CV events and CV death compared with 
other ethnic groups (53, 54).  Looking at subclinical markers of CV disease in the general 
population, A-A children and adults have higher left ventricular mass, pulse wave velocity 
(PWV) and CIMT compared to other ethnicities (55-58).  Mittelman, et al. conducted a cross- 
sectional study examining CIMT in a multiethnic population of 599 healthy children between 6 
to 20 years of age (224 Hispanic, 210 European-American, 39 Asian-American, and 126 A-A) 
(56). They reported that CIMT was greater among the A-A children than any of the other ethnic 
groups (all p<0.05), while there were no differences in CIMT between the Caucasian, Hispanic 
and Asian groups; A-A ethnicity remained a significant independent predictor of CIMT in their 
multivariate analysis (β=0.01, p=0.02) (56). Similarly, the results of our study showed that the 
CIMT of the healthy A-A control group was greater than that of the non A-A control group, 
which included  Caucasian, Hispanic and Asian children (0.47 vs 0.44 mm), p=0.02. CIMT was 
even further increased in the A-A transplant recipients compared to the A-A controls (0.49 vs. 
0.47 mm, p=0.03) at 1 and 18 months post-transplant.  In the multivariate analysis of our entire 





of increased CIMT in the general A-A population is unknown.  It remains to be seen whether it 
may be related to environmental exposures, genetic polymorphisms, or other causes. One study 
suggests that higher CIMT among individuals of African ancestry may be related to 
physiological differences in the size of CV structures and lean body mass that vary among 
different ethnic groups (59), while another study suggested that a blunted nocturnal cortisol rise, 
caused by psychosocial stress, may account for increased risk for atherosclerosis and CIMT in 
obese A-A youth (60).    
In our study, after stratifying by race, MS was identified as an independent predictor of increased 
CIMT in the A-A transplant cohort. This highlights the importance of aggressive focus on 
prevention and early detection of MS for improving CV outcomes. Studies in the general 
pediatric population suggest that diet and lifestyle changes can be effective in reducing CIMT. 
Woo et al. conducted a study investigating the effect of diet and exercise on noninvasive markers 
of atherosclerosis in otherwise healthy obese children, and found a significant improvement in 
CIMT and percent body fat after one year of intervention (82).  While ours was the first study to 
investigate the effects of MS on CIMT after transplant, a recent multicenter cross-sectional study 
conducted in Germany examined effects of individual metabolic risk factors (such as obesity 
defined by BMI and WHr, hypertension, and HDL-C), on CIMT in pediatric kidney transplant 
recipients (92). In this study, Borchert-Morlins et al. reported no significant associations of 
metabolic risk factors with CIMT in their Caucasian pediatric transplant cohort, which is in 
agreement with the lack of significant associations found within our non AA- transplant group. 
Further studies are needed to investigate why metabolic risk factors may impact the CIMT of A-





A limitation to our study was that the distribution of male and female gender was different 
between the transplant and control groups. However, gender was included in the multivariate 
regression models, and was not significantly associated with CIMT in any of the analyses.  
In summary, our findings indicate that A-A pediatric transplant recipients have increased CIMT 
compared to both A-A controls and non A-A transplant recipients.  Pre-transplant 
hyperparathyroidism contributes to increase in CIMT in the early post-transplant period. MS is 
common after kidney transplantation, occurring in about a third of non A-A children and about a 
quarter of A-A children. Early signs of CV damage, as detected by increased CIMT, are present 
in A-A pediatric kidney transplant recipients.  MS is an independent risk factor for increased 
CIMT among the A-A transplant cohort.  Identification of subclinical CV damage, detected by 
CIMT, may provide an opportunity for early CV risk stratification. Investigation of the effects of 
racial differences in CIMT and CV risk are critical to creating accurate race-specific risk 
prediction models for diverse pediatric kidney transplant recipients.  At the present time, 
normative CIMT reference values for children of different racial groups are lacking. Further 
research, particularly within the high risk A-A pediatric transplant population, is needed to make 
progress towards delaying or avoiding the occurrence of future major CV events, and increasing 









Tables     
Table 1 Demographics and characteristics of the transplant group and control groups   
 






Transplant vs  
Controls 
Age (years) 12.1+ 0.7 11.1 + 0.5 0.31 
Race (%) 50% A-A 58% A-A 0.53 
Sex   (%) 62% male 25% male 0.004* 









Duration dialysis (months) 
Hemodialysis 
Peritoneal Dialysis 







1 month  
18 months  
30 months  





Steroid protocol  
1 month  
18 months  






Steroid dose of those on 
steroid therapy 
(mg/kg/day)  
1 month  
18 months  
30 months  
















Prevalence of metabolic and cardiovascular morbidities in the transplant group at each time point 





1 month 18 
months 


















































































































Pre-transplant versus 1 month post-transplant*, Pre-transplant vs 18  months post-






CIMT of A-A and non-A-A transplant recipients at each time point vs. controls 
 Controls 
n=14 A-A 
n=10 non A-A 
Transplant Group 
n=21 A-A 







































































































NA NA 0.03* 0.62 0.03* 0.51 0.37 0.79 
*significant difference by Student’s t-test, p<0.05 







                                   
Figures 





Figure 1.  Box plots depict the CIMT of A-A and non A-A transplant 
recipients, overlaying single line indicating the CIMT of race-matched 
control patients. 
 *significant difference between A-A and non A-A transplant recipients 



































































Section 4.3: Manuscript 3 
Title: Comparison of BMI, Waist Circumference, and Waist-to-Height ratio for Identification of 
Subclinical Cardiovascular Risk in Pediatric Kidney Transplant Recipients 
Introduction 
Cardiovascular (CV) disease is the most common cause of mortality amongst children with end 
stage renal disease (128).  Chronic kidney disease is a life-long chronic illness in which 
subclinical risks to CV health begin early in the course of the disease and continue to persist after 
kidney transplantation.  Identification of clinical risk factors, such as obesity, that can predict CV 
dysfunction in children is needed for early and accurate CV risk stratification in this population.  
However, as major CV outcomes (such as myocardial infarction, stroke, or death) often don’t 
occur until young adulthood or later, evidence linking clinical risk factors to adverse CV 
outcomes in this vulnerable pediatric population has been lacking. The emergence of newer non-
invasive technology, such as carotid intima-media thickness (CIMT) and speckle tracking 
echocardiography with strain imaging, may provide the opportunity to accurately identify early 
signs of subclinical CV disease in children (36, 112). Both increased CIMT and impaired 
myocardial strain have been associated with obesity, hypertension, and dyslipidemia in children 
(129, 130) and predict major adverse CV events and mortality in adults (80, 101, 102). 
In general, obese children are known to be at higher risk for metabolic and CV abnormalities, 
including hypertension and dyslipidemia (14).  Abdominal obesity in particular has been more 
strongly associated with high CV risk than is body mass index (BMI), as obesity-related 
morbidity is more closely linked to central fat distribution rather than total body fat alone (19, 
21).  Although BMI is the most common measure of obesity used in clinical practice, evidence 
shows that both waist circumference (WC) and waist-to-height ratio (WHr) are better predictors 





pediatric kidney transplant recipients, as studies show that the prevalence of obesity doubles 
(from about 15-30%) during the first year after transplantation (25).  Factors contributing to post-
transplant weight gain include increased appetite and improved taste sensation with the 
resolution of uremia, liberalization of renal diet restrictions, as well as sedentary lifestyle and 
poor overall physical fitness, which are pervasive in this population (25).  Evidence suggests that 
BMI does not accurately reflect body composition in children with kidney disease, due to their 
short stature and altered fat deposition patterns (22, 23).  The measure of obesity that best 
predicts CV risk in pediatric kidney transplant recipients has not been established.  The objective 
of this study was to investigate and compare the ability of BMI, WC, and WHr methods to 
identify subclinical CV risk in pediatric kidney transplant recipients. 
Methods 
Study Design and Population 
A prospective, controlled cohort study was conducted to investigate the ability of BMI, WC, and 
WHr to predict subclinical CV risk, as defined by a composite adverse CV outcome, in pediatric 
kidney transplant recipients.  The composite CV outcome was comprised of traditional risk 
factors (hypertension, dyslipidemia, left ventricular hypertrophy) and non-traditional risk factors 
(impaired myocardial strain and increased CIMT) , all of which have been associated with 
obesity in children and have been shown to predict future adverse CV outcomes in adults (14, 80, 
101, 102, 127, 129, 130). In addition, we examined leptin, a biomarker of obesity associated with 
CV risk (131), in a subset of lean and obese transplant recipients as classified by BMI, WHr, and 
WC.  Pediatric kidney transplant recipients (1-30 months post-transplant) followed at Children’s 
National Health System (CNHS) in Washington DC, age 3-20 years, were eligible to participate 







nephrotic-range proteinuria were excluded.  Non-obese, healthy children with no history of 
chronic disease were enrolled as controls. Approval was obtained from the Institutional Review 
Board (IRB) at CNHS and University of Maryland College Park. Informed consent was obtained 
from all participants.  Transplant recipients had anthropometric measures, blood pressure, fasting 
lipid panel (triglycerides, LDL-C, and HDL-C cholesterol), CIMT and echocardiogram assessed 
during study visits at 1, 18, and 30 month post-transplant. A subset of 27 pediatric transplant 
recipients had leptin levels measured between 1 and 30 months post-transplant. Healthy controls 
had anthropometric measures, blood pressure, CIMT, and echocardiogram assessed at a single 
visit.  
Classification of Obesity 
Obesity was evaluated by BMI and by two different anthropometric measures of abdominal 
obesity: WC and WHr at 1, 18, and 30 months post-transplant.  BMI was calculated and 
converted to age-and-sex specific percentiles and z-scores, with BMI>95
th
 percentile defined as 
obese (119). WC was measured with a Gulick fiberglass tape measure (Country Technology, 
Gays Mills, WI) at the upper-most lateral border of the right ileum, at the end of an expiration, 
according to the NHANES procedure (105).  WC percentiles and z-scores were determined 
according to CDC age-and-sex specific tables and obesity defined as WC >95
th
 percentile (106).  
WHr was calculated as a ratio of weight in cm divided by height in cm. A WHr cut point of 
>0.539 was used to classify obese, based on NHANES data according to the method of Kahn et 
al. (19).  
Echocardiographic Methods 
An echocardiogram was obtained at 1, 18 and 30 months post-transplant. The echocardiograms 





(Philips North America Corporation, Andover, MA), according to American Society of 
Echocardiography standards (110).  Echocardiograms were analyzed using Syngo Velocity 
Vector Imaging (Siemens, Germany) by a pediatric cardiologist blinded to the subject’s clinical 
information.  Left ventricular mass indexed to height
2.7 
was evaluated by standard 
echocardiography.  Myocardial strain was assessed in the longitudinal (long-axis) direction by 
speckle tracking analysis. Strain was calculated by measuring the end systolic distance between 
two speckles of tracked endocardium minus the original distance divided by the original 
distance. Because the myocardium contracts during systole, these values are negative 
percentages, and more negative values indicate better cardiac contractility. Left ventricular 





according to the age-specific percentiles of Khoury et al. (66). As there are no established 
pediatric normative reference values for myocardial strain, the strain data of our healthy control 
group were used to establish the cut-point for high strain.  High strain was thus defined as a 
value >95
th
 percentile of our control data. 
CIMT Methods  
CIMT was assessed at 1, 18 and 30 months post-transplant. B-mode ultrasound imaging of the 
arterial far wall segments of the right and left common carotid arteries and carotid bulbs was 
performed according to a standard protocol using the iE33 xMatrix DS Ultrasound System 
(Philips North America Corporation, Andover, MA).  Intima-media thickness of the distal, mid, 
and proximal segments of right and left common carotid arteries and carotid bulbs was then 
measured by a pediatric cardiologist, and a composite of the 8 measurements was used to 





CIMT in children.  Therefore, CIMT data of our healthy control group were used to establish the 
cut-point for high CIMT.  High CIMT was defined as a value >95
th
 percentile of our control data. 
Definition of Composite Adverse CV Outcome 
We constructed a composite adverse CV outcome, consisting of five CV risk factors that have 
been individually linked with obesity in children and are known to predict adverse CV events in 
adults.  The composite adverse CV outcome was defined as the presence of at least three of the 





 percentile for age and sex (66)), 2) high CIMT (defined as >95
th 
percentile, 
based on our healthy control data), 3) high myocardial strain (defined as >95
th
 percentile, based 
on our healthy control data), 4) dyslipidemia (defined as the presence of at least one abnormal 
lipid parameter), and/or 5) hypertension.   Cut points for abnormal lipid parameters for HDL-C, 
LDL-C, triglycerides were defined according to 2011 Guidelines for Cardiovascular Health and 
Risk Reduction in Children and Adolescents (40) for study participants age 3-19, and by the 
Adult Treatment Panel III criteria (108) for >19 years of age. Hypertension was defined by 
requirement for antihypertensive medication.   
Statistical Methods 
Statistical analyses were conducted using Stata 14.0 (StataCorp LP, College Station, TX). Tests 
of proportions were performed using Chi-square analysis. Receiver Operator characteristic 
(ROC) curve analysis was used to compare the ability of BMI, WC, and WHr to detect the 
composite adverse CV outcome.  The measure of diagnostic accuracy defined by the area under 
the curve (AUC) was used to compare the predictive value of the BMI, WC, and WHr methods. 







We conducted an analysis of 116 visits of 42 pediatric kidney transplant recipients over 1 to 30 
months post-transplant.  Demographics and clinical characteristics of the study participants are 
shown in Table 1. The study population included 42 pediatric kidney transplant recipients who 
were 12.1+ 0.7 years of age. The study population was multi-ethnic, comprised of 50% African 
American, 28.6% Hispanic, 14.3% European American, 4.8% Middle-Eastern, and 2.3% Asian.  
The mean BMI z score was 0.73+0.14, mean WHr was 0.53+0.01, and mean WC z score was 
0.27+0.11.  Transplant recipients were short for age, with a mean height z-score of -1.05+0.21 at 
1 month post-transplant.   They were maintained on standard immunosuppression therapy with 
Tacrolimus and Mycophenolate Mofetil, and approximately half were receiving steroid therapy 
in addition.   
Prevalence of adverse CV outcomes among BMI, WHr, and WC-obese transplant recipients 
The prevalence and frequency of adverse CV outcomes among the BMI, WHr, and WC-obese 
transplant recipients, respectively, are shown in Table 2. The prevalence of obesity detected by 
WHr (43.5%) was significantly higher as compared to BMI (24.1%) and WC (12.0%), p= 0.002 
and p=0.02, respectively. The prevalence of dyslipidemia was higher in WHr-obese (76.6%) as 
compared to the BMI-obese (50%) and WC-obese (44.4%) transplant groups, p=0.02 and 
p=0.05, respectively. The proportion of WHr-obese transplant recipients who met the criteria for 
the composite adverse CV outcome (62.2%) was almost double compared with the proportion of 
BMI-obese (34.6%) and WC-obese (33.3%) affected by the composite adverse CV outcome.  
Distribution of obesity among transplant recipients 
Scatter plots were constructed to depict the distribution of BMI, WHr, and WC-obesity in the 





for identification of those participants that were detected as obese by WHr, but not by BMI or 
WC and vice versa.  In a comparison of the WHr and BMI methods, Figure 1 shows that 17.6% 
(19/108) of observations are categorized as obese by WHr only, whereas no observations are 
obese by BMI only.  Figure 2 compares the WC and BMI methods and shows that less than 2% 
of observations (2/108) are obese by WC only, whereas 13.9% (15/108) are obese by BMI only.  
Finally, as shown in Figure 3, a comparison of WHr and WC methods shows that 29.6% 
(32/108) of observations are categorized as obese by WHr only, whereas no (0/108) observations 
are obese by WC only. 
Leptin 
The mean leptin level of obese transplant recipients was significantly greater than that of lean 
transplant recipients by all three classification methods (BMI, WHr, and WC).  Among this 
cohort of 27 transplant patients who had leptin measured, WHr identified a greater proportion of 
children as obese by WHR (59.2%) than WC (22.2%) or BMI (18.5%), p=0.005 and p=0.002, 
respectively. The difference in leptin between lean and Whr-obese children was 10.8 + 3.9 vs. 
39.5 + 3.9 pg/mL, p= 0.00001, respectively, see Table 3.  
ROC analysis of composite adverse CV outcome 
The results of the comparison of BMI, WHr, and WC-obese methods to predict the adverse CV 
outcome by ROC analysis are shown in Figure 4.  The area under the curve (AUC) for WHr-
obese was greatest at 0.77+0.05 (95% CI 0.66-0.87).  The AUC for WHr-obese was significant 
higher compared to both BMI-obese (0.47+0.06, 95% CI 0.36-0.59) and WC obese (0.48+0.04, 
95% CI 0.40-0.56), p=0.0006.  The AUC of WC-obese and BMI-obese did not different from 





The sensitivity and specificity of WHr were both good at 75.7% and 73.9%, respectively.  The 
sensitivity of WC was very poor at 11.1%, while the specificity was good at 86.0%.  The 
sensitivity of BMI was also poor at 25.7% while the specificity was comparable to WHr at 
71.2%.  
Discussion 
Our prospective study of three different anthropometric indicators of obesity demonstrated that 
WHr is a more sensitive method than BMI or WC for identifying a subclinical adverse CV 
outcome in a population of pediatric kidney transplant recipients.  This was the first study to 
compare the ability of WHr, BMI and WC to predict CV subclinical outcome in children with 
kidney disease.  
The superior ability of WHr to detect adiposity-associated CV risk in our population was 
evidenced by significantly higher AUC when compared with BMI and WC by ROC analysis 
(Figure 4).  While all three anthropometric methods exhibited good specificity, WHr was a 
significantly more sensitive indicator of the composite adverse CV outcome. The sensitivity of 
WHr was 75.7% compared with 25.7% for BMI and only 11.1% for WC.  Similarly, when 
examining the discordant obesity groups, 17.6% of observations were detected as obese by WHr 
but not by BMI (Figure 1).  An even higher percentage, 29.6%, were obese by exclusively by 
WHr when compared to WC (Figure 3).  In addition, WHr-obese pediatric kidney transplant 
recipients had significantly higher leptin levels compared with lean children. Elevated leptin has 
been identified as a biomarker for cardiometabolic risk in previous studies of pediatric kidney 
transplant recipients (132).  Taken together, our results suggest that using WHr to assess obesity 





outcomes than BMI or WC.  Thus, an important high-risk segment of the population is missed 
when BMI or WC alone are used to assess obesity in pediatric kidney transplant recipients.  
Our results are supported by those of a general pediatric population-based analysis that compared 
the ability of BMI and WHr to identify CV risk among children (n=7657) who participated in the 
NHANES III study (19). Results of this analysis by Kahn et al. demonstrated that WHr better 
identified youth with high heart rate, elevated triglycerides, total cholesterol, and LDL-C 
cholesterol, compared with BMI.  The possible reasons behind the stronger association of WHr 
with CV risk factors are multi-fold.  Firstly, as WHr is a measure of abdominal adiposity, WHr-
obesity signifies accumulation of excess visceral adipose tissue.  Visceral adipose tissue secretes  
inflammatory cytokines, which induce a variety of  unfavorable effects including endothelial 
dysfunction, glucose intolerance, vasoconstriction, and vascular dysfunction, all of which 
increased CV risk (17).  Even in the setting of normal BMI, excess visceral adipose tissue can 
accumulate in the abdominal region when dietary lipid intake exceeds the capacity of the 
peripheral adipocytes to store it, resulting in elevated WHr (133).  In our study population, 
17.6% of children had abdominal obesity by WHr, despite having a normal BMI.  In the 
NHANES III study, WHr preferentially identified obesity in children who were shorter, had 
increased central subcutaneous fat distribution characterized by higher subscapular/triceps 
skinfold ratio, and smaller mid-thigh circumference (19).  This body type preferentially 
identified by WHr in the generally pediatric population closely mirrors the unique body habitus 
of children with kidney disease. The body composition of pediatric kidney transplant recipients 
has been characterized by central adiposity, short stature, reduced lean mass, high fat mass, and 
high trunk:leg fat mass ratio, as revealed by Dual X-ray Absorptiometry (22, 23).  Thus, WHr 





Although WC is another measure of central adiposity, WC-for-age percentiles are likely to 
underestimate abdominal obesity in children with kidney disease, due to the afore-mentioned 
issues with impaired growth and short stature, which do not allow for accurate comparisons to 
healthy age-matched peers. To this point, the sensitivity of WC to detect obesity in our transplant 
study population was extremely low at 11.1%.  
Sensitive methods for accurate detection of adiposity-associated CV risk are important in 
pediatric kidney transplant recipients due to their high risk for obesity, CV morbidity and 
mortality. As hard CV end-points are uncommon in children, we used a combination of 
traditional and non-traditional subclinical risk factors to create a composite adverse outcome for 
the detection of early signs of CV dysfunction in pediatric kidney transplant recipients.  We 
demonstrated that obesity by WHr is a more sensitive method than BMI or WC to detect the 
subclinical composite adverse CV outcome.  Therefore, WHr, a measure of abdominal obesity 
that is well-suited to assess the unique body composition of pediatric kidney transplant 
recipients, may be a superior method for detecting CV risk in this high-risk population.   
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Table 1.  





Transplant vs  
Controls 
Age (years) 12.1+ 0.7 11.1 + 0.5 0.31 
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Table 2.  Prevalence (%) of CV outcomes within the  BMI, WHr, and WC-obese transplant 
groups  
 
*significant difference in proportions by Chi-square test (p<0.05) 
 
Table 3. Mean leptin of lean and obese transplant recipients  
 Leptin (pg/mL) p value 
 Prevalence (%) of CV outcomes within the  
BMI, WHr, and WC-obese transplant groups  
 














































































































39.3 + 7.2 
(19.1-59.4) 








Chapter 5:  Summary and Future Directions 
Summary 
In summary, we found that obesity, MS and CV abnormalities are prevalent among pediatric 
kidney transplant recipients. Comparison of anthropometric methods revealed that WHr is a 
more sensitive indicator of obesity-associated adverse CV outcomes compared with BMI or WC, 
due in part to the prevalence of short stature in this population.   
Obesity, MS, and hypertension are associated with post-transplant LVH. Exposure to 
hemodialysis, as opposed to peritoneal or no dialysis, adversely impact longitudinal strain prior 
to transplant.  After transplant, significant predictors of impaired longitudinal strain include 
obesity and hypertension, whereas higher estimated glomerular filtration rate confers a protective 
effect. In addition, the interaction of MS with higher LDL-C produces an adverse effect on 
myocardial strain after transplant. The reason for this phenomenon may be explained in part by 
the specific nature of the LDL-C particles found in children with abdominal obesity, which are 
smaller, denser, and more atherogenic. In our study, transplant recipients with MS were noted to 
have an elevated TG/HDL-C ratio, which suggests the presence of such unfavorable LDL-C 
particles that may contribute to inflammation and myocardial dysfunction.   
CIMT of pediatric kidney transplant recipients is most notably affected by African American 
race.  African American pediatric kidney transplant recipients have increased CIMT, which is 
negatively impacted by MS, whereas the CIMT of non A-A children appears unaffected after 
transplant. The etiology and consequences of these differences require further investigation.   
In conclusion, obesity, MS, and A-A race adversely affect CV outcomes in pediatric kidney 





pressure, blood glucose and lipid profile after transplant. Race-specific pediatric reference values 
should be utilized, when available. Screening for obesity should include measurements of WHr 
in order to capture the full complement of adiposity associated CV risk in this population.  
Future Directions 
Large, multi-center studies are needed to further explore the findings reported in our single-
center study.  Our results suggest that WHr, a measure of abdominal obesity that is well-suited to 
assess the unique body composition of pediatric kidney transplant recipients, may be a superior 
method for detecting CV risk in this high-risk population.  Further studies that include measures 
of percent lean and fat mass in WHr-obese transplant recipients, as well as evaluation of 
additional biomarkers of adiposity, would help to further clarify the utility of WHr.  As with the 
definition of obesity, the definition of MS in the pediatric kidney transplant population may 
differ from that of the general pediatric population.  Future studies are needed to further 
investigate how the combination of MS and elevated LDL-C impacts CV outcomes of pediatric 
transplant recipients, in whom the effects of MS may not conform to the classical definition.    
Results from our racially diverse pediatric kidney transplant population also highlight the need to 
assess differences in CV risk factors and outcomes across different racial groups.  In particular, 
further studies are needed to investigate the etiology and consequences of increased CIMT in 
African American transplant recipients. Imaging techniques such as speckle tracking 
echocardiography and CIMT may provide a means of detecting subclinical CV dysfunction and 










Chapter 6: Supplemental Tables and Figures 
 
Table S1. Demographics and characteristics of the transplant group and control groups  






Tx vs  
Controls 
Age (years) 12.1+ 0.7 11.1 + 0.5 0.31 
Race (%) 50% A-A 58% A-A 0.53 
Sex   (%) 62% male 25% male 0.004* 









Duration dialysis (months) 
Hemodialysis 
Peritoneal Dialysis 







1 month  
18 months 
30 months  





Steroid protocol  
1 month 
18 months 








Table S2. Prevalence of metabolic and cardiovascular morbidities in the transplant group at each 
time point 






























































































.0009 (pre vs 1mo) 
.0001 (pre vs 18mo) 
.0002 (pre vs 30mo) 














































0.002 (pre vs 1 
months) 













0.02 (pre vs 1 
months) 
0.02 (pre vs 18 
months) 
0.008(pre vs 30 
months) 











Table S3. Skewness and Kurtosis Tests for Normality of Continuous Variables Among 
Transplant Group  
 
Variable Pr (Skewness) Pr (Kurtosis) Joint Prob>Chi
2
 
FS 0.127 0.779 0.294 
LVMI 0.000* 0.000* 0.000* 
EF 0.014* 0.001* 0.001* 
Longitudinal 
Strain 
0.562 0.181 0.339 
Circumferential 
Strain 
0.795 0.586 0.832 
BMI z score 0.916 0.198 0.429 





ln CIMT 0.067 0.108 0.058 
A-A CIMT 0.106 0.519 0.201 
nonA-A CIMT 0.04* 0.78 0.11 
lnCIMT  
nonA-A 
0.08 0.46 0.15 
WHr 0.001* 0.314 0.007* 
WC z score 0.001* 0.215 0.004* 
Triglycerides  0.000* 0.001* 0.000* 
HDL-C  0.000* 0.013* 0.001* 
LDL-C 0.000* 0.002 0.000* 
HbA1c% 0.451 0.924 0.745 
Fasting glucose 0.000* 0.000* 0.000* 
Systolic BPz 0.286 0.807 0.543 
Diastolic BPz 0.282 0.671 0.505 
*non-normal distribution, p<0.05 
 
Table S4. Skewness and Kurtosis Tests for Normality of Continuous Variables Among Control 
Group  
 
Variable Pr (Skewness) Pr (Kurtosis) Joint Prob>Chi
2
 
FS 0.03* 0.13 0.04* 
LVMI 0.04* 0.40 0.08 
EF 0.88 0.29 0.54 
Longitudinal 
Strain 
0.03* 0.15 0.04* 
Circumferential 
Strain 
0.77 0.28 0.51 
CIMT 0.22 0.78 0.42 
BMI z score 0.45 0.05 0.10 
WHr 0.43 0.46 0.52 
WC z score 0.87 0.89 0.98 
Systolic BPz 0.88 0.55 0.83 
Diastolic BPz 0.73 0.07 0.16 
*non-normal distribution, p<0.05 
 
 
Table S5. Comparison of anthropometric and blood pressure parameters of transplant and 
healthy controls groups  
 













































































































































 *significant difference between means by Student’s t-test, transplant vs. 
control, p<0.05 
#significant difference between means by Student’s t-test, transplant time 
points, p<0.05 
**significant difference between medians by Wilcoxon rank-sum, 
transplant vs. control, p<0.05 
##significant difference between medians by Wilcoxon rank-sum, 
transplant time points, p<0.05 
^unless otherwise noted 
 
 
Table S6. Significance (p values) for transplant and control group comparisons of 
anthropometric and blood pressure variables 
 
 P values 
 1 vs 18 
months 
1 vs 30 
months 




Control vs 30 
months 
BMI   
z-score 
0.11 0.21 0.52 0.03* 0.08 
WHr 
 
0.80 0.91 0.0008** 0.002** 0.002** 








0.76 0.67 0.0001* 0.0002* 0.001* 
DBP z-
score 
0.90 0.82 0.004* 0.001* 0.003* 
*significant difference between transplant and control, p<0.05 by Student’s t-test 
#significant difference between transplant time points, p<0.05 by Student’s t-test 
**significant difference between transplant and control by Wilcoxon rank-sum, non-
parametric, p<0.05 




Table S7. Comparison of anthropometric and blood pressure parameters of the obese and lean 
transplant groups  
 
 Transplant Group Control 







 Obese Lean Obese Lean Obese Lean  
BMI 






































.00001* .00001* .00001*  
 
Waist Circumference 
 Obese Lean Obese Lean Obese Lean Control 









































.0004** .004** .0005**  





















(n=16) (n=22) (n=17) (n=20) (n=14) .48) 
(n=19) 












0.00001** 0.00001** 0.00001**  
Systolic Blood Pressure z score of BMI-obese and lean 















































vs lean Tx 
0.37 0.07 0.53  
Systolic Blood Pressure z score of WC-obese and lean 























































vs lean Tx 
0.95 0.12 0.39  
Systolic Blood Pressure z score of WHr-obese and lean  

























































vs lean Tx 
0.67 0.13 .59  
























































vs lean Tx 
0.96 0.95 0.59  


























































vs lean Tx 
0.09 0.31 0.35  




























































vs lean Tx 
0.92 0.58 0.51  
*significant difference between lean and obese transplant groups by Student’s t-test, p<0.05 
#significant difference between transplant and control groups by Student’s t-test, p<0.05 
**significant difference between lean and obese transplant groups by Wilcoxon rank-sum 
## significant difference between transplant and control groups by Wilcoxon rank-sum 
 
Figure S1. Distribution of Obesity Amongst Transplant Population 
























Figure S2. ROC analysis to compare the ability of BMI, WHr, and WC obesity classification 







Table S8. Measures of standard echo, myocardial strain, and CIMT in Transplant and Controls  
































































































































































+0.67     

























































































































 P values Control vs. Transplant 
 Control vs 
Pre-tx 
Control vs 1 
months 
Control vs 18 
months 
Control vs 30 
months 
FS 0.47 0.09 0.04** 0.01** 
EF 
 
0.06 0.84 0.79 0.83 
LVMI 0.01** 0.002** 0.01** 0.02** 
Long 
Strain 
0.00001** 0.0001** 0.0004** 0.00001** 
Circumf
erential 






CIMT NA 0.42 0.89 0.95 
 *significant difference between transplant and control, p<0.05 by 
Student’s t-test 
**significant difference between transplant and control, p<0.05, by 
Wilcoxon rank-sum, non-parametric 
 
 P values Transplant Time Points 
 1 vs 18 
months 
1 vs 30 
months 
Pre-tx vs 1 
months 
Pre-tx vs 18 
months 
Pre-tx vs 30 months 





 0.10 0.07 


















CIMT 0.45 0.38 NA NA NA 
 #significant difference between transplant time points, p<0.05 by 
Student’s t-test 
##significant difference between transplant time points, p<0.05 by 
Wilcoxon rank-sum, non-parametric 
 







































Change in Fractional Shortening of 
























Change in Ejection Fraction of Transplant 

























n=24 Pre-Tx 1 month 18 months 30 months 


































































































































n=24 1 month 18 months 30 months 
























































































n=24 1 month 18 months 30 months 









































































NA 0.02** .004** 0.04** 0.02** 0.01** 0.05 
 
 
















































































































































































































































































































NA .005* .0007* 0.02* .0002* .0004* .00001* 
 

























n=24 Pre-Tx 1 month 18 months 30 months 
















































































































n=24 1 month 18 months 30 months 



















































































n=24 1 month 18 months 30 months 








































































NA 0.75 0.25 NA 0.10 0.64 0.04* 
 




















CIMT n=24 1 month 18 months 30 months 

















































































CIMT n=24 1 month 18 months 30 months 





































































CIMT n=24 1 month 18 months 30 months 
  Obese Lean 
 






























































NA 0.27 0.62 0.66 0.83 0.13 0.65 
 
 





















n=21 non A-A 





































































































NA NA 0.03* 0.62 0.03* 0.51 0.37 0.79 
*significant difference by Student’s t-test 
** significant difference by Wilcoxon rank-sum, p<0.05 
 
Figure S9. CIMT of A-A and non-AA transplant recipients at each time point vs controls 
 
 
                     Non A-A control 



















Figure S11. Pre-transplant Hyperparathyroidism and High CIMT at 1 month post-tx 
 
 
Table S14. Chi-square table of High PTH and High CIMT 
  Normal PTH  High PTH Total 
Normal CIMT 22 3 25 
High CIMT 5 4 9 
Total 27 7 34 
 
Table  S15. Biochemical indicators of transplant recipients at each time point 












































































































































































NA NA NA 





NA NA NA 
*unless otherwise noted 
 P values Transplant Time Points 
 1 vs 18 
months 
1 vs 30 
months 
Pre-tx vs 1 
months 
Pre-tx vs 18 
months 




0.79 0.84 0.37 0.28 0.39 
HDL-C 
 



















 NA NA NA 
 #significant difference between transplant time points, p<0.05 by 
Student’s t-test 
##significant difference between transplant time points, p<0.05 by 
Wilcoxon rank-sum, non-parametric 
 
Figure S12.  Change in mean triglyceride level of transplant recipients over time 
 
 































Change in Triglycerides of Transplant 


















































Table S16. Leptin levels of lean and obese transplant recipients (n=27) 
 Leptin (pg/mL) 



































*significant difference between mean leptin of lean vs. obese transplant 
Multivariate Analysis 






Output of final/best model after stepwise GEE 
regression 
BMI-obese             Odds Ratio+ SEM     p         [95% CI] 
 
BMI-Obese      3.7+1.9         0.01           1.4-9.9 
High SBPz       5.2+3.2         0.007         1.6-17.2 
High DBPz      4.7+4.4          0.10          0.74-30.0 




WHr-obese                       OR+ SEM     p        [95% CI] 
 
WHr-obese       2.8+1.3     0.03       1.08-7.1 
High SBPz        4.1+2.5     0.02      1.2-13.8                                                                
Age                   3.1+1.6     0.03       1.1-8.5                 
 
Interactions:NS 
                        
WC-obese                             OR+ SEM     p        [95% CI] 
 
WC-obese           3.5+2.7        0.09      0.80-15.5        
High SBPz          3.9+2.4        0.03      1.2-13.2 
High DBPz         5.0+4.7        0.09       0.79-31.6 
Age                     5.2+3.3        0.01      1.5-17.7 
                    
Interactions: NS 
 
MS                               OR+SEM     p        [95% CI] 
 
MS                         3.5+1.7      0.01        1.3-9.3  
High SBPz             3.7+2.5      0.05        0.98-13.8     
Age                        3.3+2.2      0.08        0.88-12.8 
 
Interactions: NS 
               
             










BMI-obese                       Coef.+ SEM     p            [95% CI] 
 
BMI-Obese      1.5 +.39     0.0001         .78- 2.3 
Hypertension    1.4+.49      0.005          .43- 2.3 
Glucose Intol    .33+.43      0.45           -.52- 1.2 
LDL-C                  .01+.01      0.29           -.01-.03 
High SBPz       -.72+.72     0.32           -2.1-.68 
Steroid dose      .63+1.0      0.55          -1.4- 2.7 
eGFR               -.04+.01     0.0001       -.06-.02 




WHr-obese                       Coef.+ SEM     p        [95% CI] 
 
WHr-obese       1.06+.42     0.01       .23-1.8 
Hypertension    1.5+.46       0.001     .62-2.4 
Glucose Intol    0.37+.45      0.41      -.51-1.2 
LDL-C                  0.01+.01      0.33      -.01-.03 
Steroid dose      0.59+1.0      0.55      -1.4-2.6 
High SBPz       -.91+.75        0.22      -2.4-.56 
Race                 -.07+.46        0.87      -.97-.83 
Sex                   0.18+.45       0.68       -.7-1.1 
eGFR               -.04+.01        0.0001   -.06 -.02 
cons                 -17.6+1.4      0.0001    -20.4 -14.8 
 
Interactions: 
                   
WHr-obese#LDL-C  .07+.02   0.0001    .04-.10 
                        
 
WC-obese                       Coef.+ SEM     p        [95% CI] 
 
WC-obese            1.6+.51     0.001       .63-2.6 
Hypertension       1.4+.46     0.003      .48-2.3 
Glucose  Intol      .56+.42     0.18        -.25-1.4 
Low HDL-C            .14+.45     0.76         -.75- 1.0 
LDL-C                     .01+.01     0.26         -.01-.03 
Steroid dose         .85+1.02   0.40          -1.1-2.8 
High SBPz          -1.1+.66    0.09         -2.4-.17 
eGFR                  -.04+.01  0.0001       -.06-.02 





Sex                      .10+.44    0.81          -.75-.96 




MS                           Coef.+ SEM     p        [95% CI] 
 
MS                          0.90+.49   0.06       -.05-1.8 
Hypertension          1.5+.47     0.002      .55- 2.4 
Glucose Intol          0.38+.50   0.45       -.60-1.3 
LDL-C                         0.01+.01   0.30       -.01-.03 
Steroid  dose           0.54+1.04  0.59       -1.5-2.6 
High SBPz              -.95+.77     0.22       -2.6-.55 
Sex                          0.12+.48    0.53       -.82-1.0 
Race                       -0.15+.47    0.75       -1.1-.77 
eGFR                      -0.04+.01   0.0001    -.06-.02 
cons                      -17.5+1.4   0.0001    -20.2 -14.7 
 
Interactions: 










Output of final/best model after stepwise GEE 
regression 
BMI-obese                         Coef.+ SEM     p            [95% CI] 
 
BMI-obese      -0.02+0.01      0.16        -0.04-0.01 
Steroid therapy-0.02+0.02     0.09       -0.06-0.004 
Race                 0.09+0.01      0.0001    0.06-0.12                
 
WHr-obese                         Coef.+ SEM     p        [95% CI] 
 
WHr-obese      -0.01+0.01      0.68       -0.03-0.02 
Steroid therapy-0.02+0.01     0.11       -0.05-0.005 
Race                 0.09+0.01      0.0001    0.06-0.12                
 
WC-obese                         Coef.+ SEM     p        [95% CI] 
 
WC-obese       0.01+0.02       0.63       -0.03-0.05 
Steroid therapy-0.03+0.01     0.09      -0.06-0.004 






MS                         Coef.+ SEM     p        [95% CI] 
 
MS                  0.01+0.01         0.16      -0.01-0.04 
Steroid therapy-0.02+0.01      0.10      -0.05-0.005 
Race                 0.10+0.01      0.0001    0.06-0.13 
 
 





Output of final/best model after stepwise GEE 
regression 
BMI z score                      Coef.+ SEM     p          [95% CI] 
 
BMI z           0.01+0.006      0.06      -0.001-0.02 
Dyslipidemia 0.01+0.01       0.25       -0.01-0.03 
Steroid therapy 0.02+0.02     0.11      -0.01-0.06 
Sex                -0.01+0.02       0.46      -0.04-0.02 
Cons             0.43+0.02       0.0001    0.38- 0.48 
WHr 
 
                         Coef+ SEM     p        [95% CI] 
 
WHr                     0.09+0.09    0.31     -0.1-0.28    
SBP z score       -0.01+0.004   0.23     -0.01-0.003    
Age                   0.004+0.01     0.75     -0.02-0.02 
eGFR             0.001+0.0002    0.01 0.0001-0.0009 
Cons                   0.36+0.05    0.0001 0.26-0.45     
WC z score                         Coef.+ SEM     p        [95% CI] 
 
WC z            -0.004+0.005    0.48  -0.01-0.01 
Chronic HTN 0.005+0.009   0.60 -0.01-0.02 
SBP z score   -0.004+0.003   0.17 -0.01-0.02 
Steroid therapy 0.001+0.02   0.96 -0.03-0.03 
Age                 -0.002+0.01    0.87 -0.02-0.02 
eGFR          0.0006+0.0001 0.0001 0.0002-0.0009 
Cons               0.39+0.02      0.0001 0.35-0.44 
MS 
 
                        Coef.+ SEM     p        [95% CI] 
 
MS                   0.03+0.01      0.002    0.01-0.05      
Steroid therapy -0.007+0.01  0.80    -0.02-0.02 
Sex                   0.003+0.01   0.79    -0.02-0.02 
eGFR       0.000004+0.0002 0.98  0.0003-0.0003 












Output of final/best model after stepwise GEE 
regression 
BMI z score                         Coef.+ SEM     p            [95% CI] 
 
BMI z              -0.02+0.02     0.18       -0.05-0.01 
Steroid therapy-0.05+0.03     0.09      -0.11—0.01 
WHr                         Coef.+ SEM     p        [95% CI] 
 
WHr                 0.10+0.12    0.40    -0.14-0.34 
Steroid therapy -0.04+0.02   0.06    -0.1—0.001      
WC z score                           Coef.+ SEM     p        [95% CI] 
      
WC z                -0.001+0.01     0.97      -0.03-0.03 
Steroid therapy-0.04+0.03       0.16       -0.09-0.01 
MS                       Coef.+ SEM     p        [95% CI] 
 
MS                  -0.01+0.02       0.67  -0.05-0.03 
Steroid therapy-0.05-0.03       0.06  -0.1-0.001 
 





Output of final/best model after stepwise 
multivariate logistic regression 
 
 
      Coef. + SEM     p          [95% CI] 







Output of final/best model after stepwise 
multivariate logistic regression 
Pseudo R2= 0.45  
 
 
        Coef. + SEM     p         [95% CI] 
HD History             -1.3+1.3      0.33        [-3.9-1.3] 
Hypertension             -1.4+1.1      0.20        [-3.7-0.7] 
Race              2.7+1.4      0.06        [-.09-5.4] 
BMI-Obese              3.8+1.8      0.03        [0.32-7.3] 
High iPTH              1.8+1.6      0.25        [-1.3-5.0] 













Output of final/best model after stepwise 




  Coef.+ SEM     p          [95% CI] 
Dialysis History       1.2+2.1       0.57         (-3.2-5.6) 
HD History       4.0+1.9       0.04*       (0.1-7.9) 
Hypertension     0.36+1.7      0.84          (-3.3-4.0) 
Race      -1.7+1.7      0.31          (-5.2-1.8) 
Age      -1.4+1.8      0.47          (-5.3-2.6) 
BMI-Obese       4.5+2.4      0.08          (-0.6-9.7) 
High iPTH     -0.89+1.8     0.63          (-4.7-3.0) 









Output of final/best model after stepwise 





     Coef.+ SEM     p         [95% CI] 
Dialysis History          2.4+1.7       0.18       (-1.2-6.0) 
HD History         -1.1+1.7       0.52       (-4.6-2.4)                     
Chronic HTN          0.4+1.2       0.73       (-2.0-2.8)            
Race          0.1+1.3       0.91       (-2.6-2.9)            
Age          0.1+1.3       0.47       (-1.7-3.7) 
BMI-Obese          3.6+1.6      0.04*      (0.19-6.9) 
High iPTH         -0.26+1.5   0.86        (-3.4-2.9) 








Output of final/best model after stepwise multivariate 
linear regression 
R2 = 0.45 
 
 
    Coef.+ SEM          p            [95% CI] 
History of HD        -4.6+2.6          0.11          (-10.5-1.3)       
Race        -0.5+2.9          0.86          (-7.3-6.3) 
Sex         1.1+2.5          0.67          (-4.7-6.9) 
BMI-Obese         4.4+4.0          0.30          (-4.9-13.8)  
High iPTH         0.9+2.7          0.76          (-5.4-7.2) 
Dyslipidemia         1.3+3.3          0.71          (-6.4-9.1) 













Output of final/best model after stepwise multivariate 
logistic regression 




              Coef+SEM              p                [95% CI] 
High  
iPTH 
                 3.8+1.9                0.04             0.16-7.6 
Hypertension                   2.7+1.5                0.08             -.33-5.8 
Hx dialysis                  -3.1+1.7                0.07              -6.4-.23 
Dyslipidemia                  -2.5+1.3                0.06              -5.1-0.1 
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